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Abstract 
Airway mucus obstruction is a key feature of a spectrum of chronic lung diseases such as 
cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and asthma. Mucus 
dehydration and mucin hypersecretion have been implicated in the pathogenesis of airway 
mucus plugging. However, understanding of relative contributions and combined effects of 
these abnormalities remain poorly understood. Mucus accumulation in the airways is 
associated with chronic airway inflammation. The type 2 cytokine interleukin (IL)-13 has 
been shown to play a crucial role during type 2 airway inflammation. Furthermore, IL-13 
mediates mucin overproduction by acting on airway epithelial cells. If the airway epithelium 
itself contributes to IL-13 production under conditions of muco-obstructive lung disease is 
not well understood.  
In this study, the airway epithelium was investigated as a cellular source for IL-13 production 
in transgenic (Tg) mice with airway-specific overexpression of the β-subunit of the epithelial 
sodium channel (Scnn1b) exhibiting airway mucus obstruction due to airway surface 
dehydration and a spontaneous type 2 airway inflammation at juvenile ages. IL-13 protein 
and gene expression was studied in the airway epithelium from naïve and allergen-treated 
wild-type (WT) and Scnn1b-Tg mice. In vitro studies were performed to elucidate signaling 
pathways that induce epithelial IL-13 expression. To better understand the in vivo 
pathogenesis of airway mucus obstruction, the relative roles of airway surface dehydration 
and IL-13-mediated mucin hypersecretion were investigated. Therefore, juvenile Scnn1b-Tg 
mice with genetic deletion of IL-13 (Scnn1b-Tg/Il13-/-) were studied and the phenotypes of 
Scnn1b-Tg mice were compared to mice with airway-specific overexpression of IL-13  
(Il13-Tg). By studying Scnn1b-Tg/Il13-Tg/Il13-/- mice, the combined effect of both defects 
were investigated.  
The airway epithelium from Scnn1b-Tg mice was shown to produce increased levels of  
IL-13. Epithelial IL-13 production was induced by IL-33 via the St2/Myd88/p38 signaling 
pathway. Furthermore, IL-13 specifically overexpressed in airway epithelial cells  
(Il13-Tg/Il13-/-) was sufficient to cause muco-obstructive lung disease associated with mucus 
plugging, severe goblet cell metaplasia (GCM), and airway inflammation. Scnn1b-Tg/Il13-/- 
mice displayed neither goblet cells nor mucin hypersecretion, but mucus plugging persisted 
in the airways. In Scnn1b-Tg mice, airway mucus plugging was more severe than in Il13-Tg 
mice, although Il13-Tg mice demonstrated a pronounced GCM and Muc5ac expression. 
These differences were associated with an impaired mucociliary transport in Scnn1b-Tg 
mice and a normal mucociliary transport in Il13-Tg mice. Combination of airway surface 
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dehydration and IL-13-induced mucin hypersecretion produced severe mucus plugging 
causing neonatal mortality of Scnn1b-Tg/Il13-Tg/Il13-/- mice.  
In summary, these results demonstrate that the airway epithelium provides a source of IL-13 
production in spontaneous and allergen-induced type 2 airway inflammation in juvenile 
Scnn1b-Tg mice and indicates that IL-33 contributes to this process in vivo. Further, these 
results suggest that both airway surface dehydration and IL-13-induced mucin 
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Zusammenfassung 
Mukusobstruktion von Atemwegen ist ein Hauptmerkmal von chronischen 
Lungenkrankheiten wie zystischer Fibrose (CF), chronisch obstruktiver Lungenerkrankung 
(COPD) und Asthma. Es wird angenommen, dass eine Überproduktion von Mukus und die 
Dehydratation der Atemwegsoberfläche zur Ausbildung von hyperkonzentriertem und sehr 
viskosem Mukus führen. Die relative Bedeutung dieser pathologischen Mechanismen auf 
die Mukusobstruktion ist bisher nicht untersucht worden. Die Pathogenese der 
Mukusobstruktion geht mit einer chronischen Entzündung der Atemwege einher. Hierbei 
nimmt das Typ 2 Zytokin Interleukin (IL)-13 eine zentrale Rolle ein, da es die Typ 2 
Atemwegsentzündung fördert und eine vermehrte Muzinproduktion in den Becherzellen des 
Atemwegepithels induziert. Inwiefern Epithelzellen in muko-obstruktiven Atemwegen selbst 
IL-13 produzieren können, ist jedoch nicht bekannt. Deshalb wurde in dieser Arbeit die 
epitheliale IL-13 Produktion in juvenilen transgenen (Tg) Mäusen mit einer 
atemwegsspezifischen Überexpression der β-Untereinheit des epithelialen Natriumkanals 
(Scnn1b) untersucht. Diese Mäuse weisen aufgrund einer Atemwegsdehydratation einen 
muko-obstruktiven Phänotyp sowie eine Typ 2 Atemwegsentzündung auf. Im 
Atemwegsepithel von naiven und allergenbehandelten Wildtyp (WT)- und Scnn1b-Tg 
Mäusen wurde die Protein- und Genexpression von IL-13 bestimmt sowie die zugrunde 
liegende Signalkaskade in vitro untersucht. Des Weiteren sollte geklärt werden, welchen 
Einfluss die Atemwegsdehydratation im Vergleich zur IL-13-vermittelten 
Muzinhypersekretion auf die Pathogenese der Mukusobstruktion in vivo haben. Zum einen 
wurden hierzu juvenile IL-13-defiziente Scnn1b-Tg (Scnn1b-Tg/Il13-/-) Mäuse untersucht und 
zum anderen wurden Scnn1b-Tg Mäuse mit atemwegsspezifisch IL-13-überexprimierenden 
Mäusen verglichen (Il13-Tg). Mit Hilfe von Scnn1b-Tg/Il13-Tg/Il13-/- Mäusen wurde 
untersucht, welche Auswirkung das gleichzeitige Auftreten von Atemwegsdehydratation und 
IL-13-vermittelter Muzinhypersekretion auf die Mukusobstruktion hat. 
Es konnte gezeigt werden, dass Atemwegsepithelzellen von Scnn1b-Tg Mäusen IL-13 
produzieren und die epitheliale Il13 Expression durch IL-33 via St2/Myd88/p38 induziert 
wird. Die Überexpression von IL-13 im Atemwegsepithel (Il13-Tg/Il13-/-) war ausreichend, 
um Mukusobstruktion, Becherzellmetaplasie und Atemwegsentzündung in Mäusen 
hervorzurufen. Im Vergleich zu Scnn1b-Tg Mäusen wiesen Scnn1b-Tg/Il13-/- Mäuse weder 
Becherzellen noch eine vermehrte Muzinproduktion auf, jedoch keine verminderte 
Mukusobstruktion. In Scnn1b-Tg Mäusen war die Mukusobstruktion stärker ausgeprägt als 
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in Il13-Tg Mäusen, obwohl Il13-Tg Mäuse eine Becherzellmetaplasie und eine erhöhte 
Muc5ac Expression aufwiesen. Dieser Unterschied zwischen den Modellen korrelierte mit 
einer unterschiedlichen Effektivität des mukoziliären Transports, welcher in Scnn1b-Tg 
Mäuse deutlich vermindert und in Il13-Tg Mäusen nicht beeinträchtigt war. In Scnn1b-
Tg/Il13-Tg/Il13-/- Mäusen hatte eine schwerwiegende Mukusobstruktion der Atemwege eine 
frühzeitige Mortalität innerhalb der ersten Lebenswoche zur Folge. 
Zusammenfassend zeigt diese Arbeit, dass Atemwegsepithelzellen von juvenilen  
Scnn1b-Tg Mäusen mit einer Typ 2 Entzündung IL-13 produzieren und hierbei IL-33 als 
Stimulus eine wichtige Rolle spielt. Weiterhin deuten die Ergebnisse daraufhin, dass sowohl 
die Atemwegsdehydratation als auch die IL-13-vermittelte Muzinhypersekretion einen 
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1 Introduction 
1.1 Pathophysiological aspects of muco-obstructive lung 
diseases 
Airway mucus obstruction is a critical pathogenic feature of several chronic lung diseases 
such as CF, COPD, and asthma. It contributes to airflow obstruction, pathogen colonization 
and chronic inflammation and affects disease severity.1 CF is one of the most common 
autosomal recessive genetic diseases in Caucasian populations and results from mutations 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leading to an 
imbalance of the ion transport on epithelial surfaces.2-4 Although CF is a multi-organ 
disease, progressive lung disease associated with airway mucus obstruction is the major 
cause of morbidity and mortality in CF patients.5 In CF lung disease, the build-up of thick 
and sticky mucus in the airways provides a nidus for bacterial infections with Pseudomonas 
aeruginosa being the most abundant pathogen.6,7 This contributes to chronic airway 
inflammation dominated by neutrophilic infiltrates associated with elevated concentrations of 
IL-1, IL-6, IL-8, and tumor necrosis factor (TNF)-α.8 COPD is primarily caused by cigarette 
smoking and characterized by chronic bronchitis and emphysema. Small airway mucus 
obstruction due to inflammation-induced mucus overproduction contributes to airflow 
limitations in COPD and correlates with disease severity.9 Bacterial and viral infection are 
often associated with exacerbations and disease progression.10 Airway inflammation in 
COPD is diverse; increased numbers of activated macrophages and neutrophils as well as 
CD8+ and CD4+ (predominantly T helper (Th)1 and Th17) lymphocytes are found in sputum 
and bronchoalveolar lavage (BAL) fluid of patients with COPD, and at least in subgroups of 
patients a type 2 immune response with increased levels of eosinophils and Th2 cells is 
observed.11 An emerging concept is that mucus obstruction can trigger sterile inflammation. 
In recent years efforts were undertaken to investigate neutrophilic inflammation in the 
absence of infection, as observed in children with CF and patients with COPD.12-14 Mucus 
plugging was shown to cause cellular hypoxia due to necrosis of epithelial cells15, which is a 
potent stimulus for sterile neutrophilic inflammation in muco-obstructed airways.16,17 Further, 
inhaled non-microbial irritants, such as cigarette smoke, accumulate in adhesive mucus and 
induce sterile inflammation by activating resident macrophages and airway epithelial cells to 
release inflammatory mediators attracting circulating leukocytes into the lung.18 In patients 
with asthma, obstruction of the conducting airways is driven by mucus plug formation and 
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smooth muscle contraction in response to stimuli such as allergens or cold air leading to 
airway hyperresponsiveness (AHR).19,20 Postmortem studies identified airway mucus 
plugging as the principle cause of death that is highlighted in fatal asthma cases.21,22 Allergic 
asthma is primarily characterized by type 2 airway inflammation, which is initiated by the 
airway epithelium serving as a target and potent effector tissue for pulmonary immune 
responses against allergens. Through pattern-recognition receptors that recognize 
pathogen- and damage-associated molecular patterns, airway epithelial cells get activated 
and release chemokines, growth factors, endogenous danger signals, and cytokines 
including IL-25, IL-33, and thymic stromal lymphopoietin (Tslp).23 The alarmin IL-33 was 
reported to most potently stimulate Th2 cells and type 2 innate lymphoid cells (ILC2s) to 
secrete IL-4, IL-5, and IL-13.24-26 These type 2 signature cytokines in turn promote the 
recruitment of eosinophils and alternatively activated macrophage differentiation.24  
1.2 Mucus clearance system of the lung 
In health, airways are covered by a thin airway surface liquid (ASL) layer that mediates 
effective mucociliary clearance (MCC). The ASL consists of two gel layers, a mobile mucus 
layer that traps environmental irritants, inhaled pathogens, and cellular debris, and beneath 
a periciliary layer (PCL).27 To keep airways free of potentially inflammatory stimuli, the 
mucus together with entrapped particles is propelled by ciliary beating within the PCL toward 
the pharynx where it can be swallowed or expectorated by coughing. Button et al. 
demonstrated that a dense mesh of large membrane-bound mucins, tethered to cilia and 
epithelial cells, prevent a penetration of secreted mucins and deposited particles from the 
mucus layer into the PCL.27 The mucus layer is a viscoelastic gel that consists of secreted 
mucins, globular proteins, ions, lipids, and water. Mucins are complex glycoproteins 
characterized by large molecular weight and high carbohydrate content that are mostly  
O-linked glycans.28 Their ability to form polymers is critical for gel formation and thus 
viscoelastic properties of mucus.28 The mucins are stored in a condensed form in granules. 
Upon exocytosis, they are hydrated and unpacked by ion exchange of Na+ for Ca2+, which is 
chelated by HCO3
- on the apical airway surface.29 The major secreted mucins of the 
respiratory tract are MUC5B and MUC5AC. MUC5B is constitutively expressed and 
predominantly produced by secretory cells of the submucosal glands, whereas MUC5AC is 
secreted by goblet cells lining the airway surface and its expression is more regulated.28,30 
The pulmonary clearance system requires a coordinated regulation of mucin synthesis and 
secretion, coordinated ciliary beating and appropriate ion transport for a proper hydration 
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status. The hydration of airway surfaces is determined by transepithelial ion transport 
pathways that are mainly mediated by Na+ absorption across the apical plasma membrane 
mediated by the epithelial Na+ channel ENaC and Cl- secretion driven by CFTR and 
alternative Cl- channels, such as TMEM16A and SLC26A9.5,31 The fluid passively follows 
along the electrochemical gradient, thereby regulating the ASL height.  
1.3 Abnormal mucus properties in CF, COPD, and asthma 
Several pathologies lead to a failure of the pulmonary mucus clearance system resulting in 
airway mucus obstruction. Current concepts predict that hyperconcentrated mucus is a 
critical factor causing impaired MCC.27 The mucus concentration can be measured as 
percent solids and was shown to correlate with the mucus osmotic pressure. A high solid 
content of the mucus layer (hyperconcentrated mucus) increases its osmotic pressure by 
drawing water from the PCL. Above a certain threshold, the mucus layer-related osmotic 
pressure exceeds the osmotic pressure of the PCL, which results in the compression of 
subjacent cilia, impaired ciliary beating and mucus adhesion to airway cells.27,32 Button et al. 
suggest two scenarios that lead to impaired MCC as a result of hyperconcentrated mucus.27 
First, mucus dehydration due to a dysregulation of the ion transport across the airway 
epithelium causes ASL volume depletion, thereby increasing the concentration of secreted 
mucins. This is most apparent in airways from CF patients, where Cl- secretion is impaired 
and Na+ absorption is increased. Consequently, water is removed osmotically from the PCL 
creating a dehydrated airway surface, which results in highly viscous mucus and mucus 
adhesion. Second, excessive secretion of mucins triggered by a broad spectrum of 
inflammatory stimuli increases the mucus concentration and removes water from the PCL, 
thus slowing mucus clearance, which can end up in mucus stasis. Increased mucin 
expression is an issue in CF airways, but upregulated mucin expression occurs rather 
secondary to mucus plugging as a result of inflammation and bacterial infection. Studies 
from Henderson et al. indicate that in CF airways mucus obstruction is primarily caused by 
airway dehydration.33 This is supported by recent in vitro data from Abdullah et al. showing 
that the failure of proper fluid secretion rather than abnormal inflammation-induced mucin 
secretion affects the formation of hyperconcentrated mucus in CF.34 Another factor that 
alters mucus structure and impairs MCC is mucin crosslinking via disulfide bonds in 
response to oxidative stress, such as reactive oxygen species arising from airway 
inflammation.35 Further, HCO3
- deficiency in CF airways, due to a reduced CFTR-mediated 
HCO3
- secretion, impairs proper mucin hydration by reduced Ca2+ chelation and contributes 
Introduction   
4   
to viscous mucus formation.29 In vitro studies by Abdullah et al. indicate that airway 
dehydration rather than low HCO3
- concentrations is the major determinant for defective 
mucin unfolding in CF.36 
In COPD, the muco-obstructed phenotype is most likely driven by both mucin hypersecretion 
and airway dehydration. A recent study by Anderson et al. demonstrates that in patients with 
chronic bronchitis, mucus hyperconcentration is associated with impaired MCC and disease 
severity.32 Emerging evidence suggests that cigarette smoke causes CFTR dysfunction and 
thus a reduced capacity to secrete fluid due to an ion transport imbalance.31 Further, 
cigarette smoke can directly upregulate mucin expression via cigarette smoke-containing 
toxins, or indirectly by activation (e.g. through reactive oxygen species) of epithelial cells and 
innate immune cells, such as neutrophils and macrophages, which in turn produce mucin-
inducing factors.18,37-40 In addition, viral and bacterial infections contribute to mucus 
overproduction in COPD.41,42  
Asthma has also been associated with impaired MCC43,44 and airway mucus hypersecretion 
constitutes a typical pathophysiological feature of asthma.45,46 It is well established that 
inflammatory cells and their mediators, such as IL-13, induce an increase in mucus-
producing cells as well as mucin synthesis and secretion in asthmatic airways.47 However, 
the relationship between hyperconcentrated mucus, reduced MCC, and mucin 
hypersecretion in asthma is not well known. Recent studies on the role of mucus 
composition and the functional properties of MUC5AC and MUC5B yielded new insights to 
this issue. Mucus composition in COPD and CF differs from that in asthma patients. In 
COPD, both mucins are upregulated48, whereas increased MUC5B levels are characteristic 
for CF lung disease.30 In asthmatic patients, gene expression for MUC5AC is increased in 
epithelial cells49,50, and MUC5AC is the predominating mucin in sputum samples.45,51,52 
Recently it was observed that MUC5AC-rich mucus is tethered to airway epithelial cells, 
thereby making the mucus more adhesive53, and Muc5ac-meditated mucus plugging is 
required for airway hyperresponsiveness in allergic airway diseases.54 Further, Muc5ac is 
highly fucosylated, increasing mucus viscoelasticity and promoting mucus aggregation.55 
MUC5B levels remained stable in some asthma patients, but in most patients they were 
reduced and associated with pronounced eosinophilc inflammation.45,49,51,56 Data by Dunican 
et al. indicate that mucin crosslinking due to eosinophil-driven oxidation contributes to 
mucus plug formation in asthma.19 Of note, Roy et al. revealed the essential role of Muc5b 
for effective MCC in a mouse model57, but whether a reduction in MUC5B contributes to 
mucus dysfunction in asthma is not known.  
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1.4 IL-13-mediated inflammation and muco-obstructive lung 
diseases 
The type 2 signature cytokine IL-13 plays a central role in the pathogenesis of allergic 
airway inflammation and is increased in asthmatic patients.56,58-61 Several studies 
demonstrated a contribution of type 2 inflammation with elevated IL-13 levels to chronic 
airway inflammation in CF and COPD.62-66 Moreover, an increased type 2 immune response 
develops in patients with allergic bronchopulmonary aspergillosis (ABPA) that is a 
hypersensitivity reaction to the fungus Aspergillus occurring in patients with CF6,67, 
COPD68,69, and asthma70,71. Under conditions with overlapping clinical symptoms of asthma 
and COPD (asthma-COPD-overlap syndrome, ACOS), IL-13 effector function becomes 
even more relevant.72-74 In airway inflammation IL-13 is predominantly produced by ILC2s 
and Th2 cells.24,75 Mediated by the IL-4Rα/IL-13Rα1 receptor complex, IL-13 promotes 
subepithelial fibrosis, bronchial eosinophilic inflammation, activation of alternatively activated 
macrophages, AHR, and mucus overproduction (Figure 1).76,77  
 
 
Figure 1. IL-13 effector functions in the lung. By acting on airway epithelial cells (AEC), IL-13 
induces goblet cell metaplasia (GCM), mucin production, and Cl
-
 secretion. IL-13 activates fibroblasts 
and enhances extracellular collagen deposition causing subepithelial fibrosis. Recruitment of 
eosinophils and induction of alternatively activated macrophages (AAM) by IL-13 promotes type 2 
airway inflammation. IL-13 induces proliferation and contraction of airway smooth muscle cells that 
triggers airway hyperresponsiveness (AHR). Modified from Gour et al.
78
 and Oh et al.
79
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Despite sharing receptor components and regulatory pathways with IL-4, IL-13 possesses 
distinct effector functions in pulmonary inflammation independent of IL-4.78 Kuperman et al. 
demonstrated that IL-13 is sufficient to induce AHR, goblet cell metaplasia, and mucin 
expression through direct interaction with airway epithelial cells.77 Binding of IL-13 to the  
IL-4Rα/IL-13Rα1 receptor results in the activation of various transcription factors that are 
involved in mucus production (Figure 2). Induction of signal transducer and activator of 
transcription 6 (Stat6) activates expression of SAM pointed domain containing ETS 
transcription factor (Spdef).80 Spdef inhibits forkhead box protein A 2 (Foxa2)80, which is 
required for maintenance of normal differentiation of airway epithelial cells81, allowing the 
induction of other genes important in goblet cell differentiation including Foxa3, chloride 
channel accessory 1 (Gob5), and transmembrane member 16A (TMEM16A).82,83 The latter 
is a Ca2+-activated Cl- channel that was shown to be involved in Muc5ac expression83 and 
mucin release from granules into the airway lumen.84 Gob5 also induces Muc5ac expression 
via p38 mitogen-activated protein kinases (MAPK)-mediated signaling.65  
 
 
Figure 2. Mechanisms of IL-13-induced goblet cell metaplasia. Various stimuli (e.g. cell damage, 
inhaled allergens, respiratory viruses) induce the secretion of IL-33 by airway epithelial cells. As an 
alarmin, IL-33 is constitutively expressed and stored in the nucleus of airway epithelial cells. Upon 
release, IL-33 acts on Th2 cells and ILC2s, which then produce IL-13. IL-13 binds to the receptor 
complex IL-4Rα/IL-13Rα1 on airway epithelial cells leading to Stat6 activation. Stat6 hetero-dimers 
translocate to the nucleus and induce Spdef expression. Spdef inhibits Foxa2, which regulates 
normal airway epithelial differentiation, allowing the induction of genes associated with goblet cell 
differentiation including Gob5, Foxa3, and Muc5ac. Gob5 increases Muc5ac expression by activation 
of p38 MAPK via a putative Gob5 receptor. Mucin transcription is further induced by Foxa3. Mucin 
molecules are tightly packed in secretory granules within the goblet cell. Modified from Gour et al.
78
 
and Erle et al.
85
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The transcription factor FOXA3 was found to be elevated in goblet cells in tissue from COPD 
and asthma patients and can also be activated by IL-13, independent of SPDEF.86 IL-13 is 
thought to decrease ciliary beat frequency, as shown in primary human nasal epithelial cells 
in vitro.87 Further, IL-13 modulates the ion transport across the airway epithelium by 
mediating down-regulation of Na+ absorption and up-regulation of Cl- secretion, and by the 
induction of many genes encoding for ion channels and transporters, such as  
TMEM16A.88-90 Recent data identified the alternative Cl- channel Slc26a9 to be stimulated by 
IL-13 in vivo and a polymorphism in the SLC26A9 gene causing a reduced protein 
expression, was linked to asthma.91 
1.5 Mouse models for muco-obstructive lung diseases 
1.5.1 Scnn1b-Tg mouse model 
The Scnn1b-Tg mouse mimics key pathologies of muco-obstructive lung diseases including 
CF, COPD, and asthma. In this mouse model, the β subunit of the epithelial Na+ channel 
(βENaC, encoded by the Scnn1b gene) is constitutively overexpressed under control of the 
club cell secretory protein (CCSP) promoter. This leads to an airway-targeted exaggerated 
Na+ and water absorption from the airway lumen causing ASL volume depletion, mucus 
hyperconcentration, and impaired MCC.92 Consequently, Scnn1b-Tg mice exhibit airway 
mucus obstruction, GCM, reduced bacterial clearance, spontaneous chronic airway 
inflammation, and structural lung damage including alveolar wall destruction and airspace 
enlargement.15,92-94 Longitudinal studies demonstrated that chronic airway inflammation in 
adult Scnn1b-Tg mice is predominantly neutrophilic, whereas at neonatal and juvenile ages 
inflammatory response is skewed towards type 2 immunity including increased levels of 
eosinophils, IL-13, and alternatively activated macrophages.15,95 Moreover, Fritzsching et al. 
recently demonstrated that in juvenile Scnn1b-Tg mice eosinophilic inflammation, secretion 
of type 2 signature cytokines and AHR are aggravated due to impaired allergen clearance 
and type 2 biased immunity at the juvenile age.95 These studies demonstrated that the 
phenotype of the Scnn1b-Tg mouse model shares key features of muco-obstructive lung 
disease in humans96-98, and beyond this provides a model to investigate mediators of the 
type 2 immune response and to study muco-obstructive lung disease primarily triggered by 
airway surface dehydration.  
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1.5.2 Il13-Tg mouse model 
Initially, Zhu et al. demonstrated that mice with airway epithelial-specific overexpression of 
IL-13 (under control of CCSP promoter) develop a phenotype that recapitulates many 
features of asthma.76 The pathology of Il13-Tg mice is characterized by AHR and 
spontaneous type 2 airway inflammation including eosinophilia and increased levels of 
eotaxin, IL-4, and IL-5.76,77 GCM and overproduction of mucus associated with upregulated 
expression of Muc5ac are also striking pathologic features of this mouse model, thereby 
mimicking muco-obstructive lung disease.76,77 Further, Il13-Tg mice show transforming 
growth factor (TGF)-β-mediated subepithelial fibrosis and develop enhanced lung volume 
and pulmonary compliance mediated by IL-13-induced matrix metalloproteinases and 
cathepsin-dependent emphysema.99,100 
1.6 Aim of the thesis 
Based on preliminary data from our group in which IL-13 could be detected in the airway 
epithelium from juvenile Scnn1b-Tg mice, the first goal of the thesis was to elaborate these 
findings by analyzing IL-13 production in airway epithelial cells from juvenile WT and 
Scnn1b-Tg mice by immunohistochemistry and laser micro-dissection. Previous studies 
demonstrated that type 2 inflammation is exaggerated in response to allergen challenge in 
juvenile Scnn1b-Tg mice with impaired MCC.95 To study if epithelial IL-13 production is also 
affected, WT and Scnn1b-Tg mice were treated with the natural aeroallergen Aspergillus 
fumigatus (Af) and epithelial IL-13 production was determined. To elucidate a signaling 
pathway of epithelial-mediated IL-13 production, studies in murine primary tracheal epithelial 
cells were performed.  
The second goal was to investigate the relative contributions of airway surface dehydration 
and IL-13-induced mucin hypersecretion to the pathogenesis of airway mucus obstruction. 
To achieve this goal, the muco-obstructive phenotype of Scnn1b-Tg mice was compared to 
that of Il13-Tg mice. Further, Scnn1b-Tg mice lacking IL-13 expression (Scnn1b-Tg/Il13-/-) 
were studied. The severity of mucus plugging, goblet cell numbers, mucin expression levels, 
mucociliary transport efficiency, and airway inflammatory cells were determined in these 
mouse models. Il13-Tg/Il13-/- mice were used to study the in vivo effect of airway epithelial 
cell-mediated IL-13. Finally, mice that exhibit both airway surface dehydration and mucin 
hypersecretion were analyzed (Scnn1b-Tg/Il13-Tg/Il13-/-) to evaluate combined effects of 
these pathologic features. 
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2 Material and Methods 
2.1 Experimental animals 
All animal studies were approved by the local animal welfare authority “Regierungs-
präsidium Karlsruhe, Germany” (35-9185.81/G-26/14). Scnn1b-Tg mice were generated as 
previously described92, maintained as heterozygous and studied on the C57BL/6N 
background. Il13+/eGFP mice were kindly provided by the laboratory of Dr A.N.J. McKenzie 
and backcrossed onto the C57BL/6N background, and referred to as Il13+/-. Il13eGFP/eGFP 
mice were used as knockout mice101 and referred to as Il13-/-. CCSP-rtTA-Il13-Tg mice 
(originally generated by Dr J. Elias) were kindly provided by Dr H. Fehrenbach, maintained 
as heterozygous on the C57BL/6N background, and referred to as Il13-Tg. These mice were 
not exposed to doxycycline containing water, because gene expression analysis of Il13 in 
lung homogenates demonstrated a leaky rtTA-mediated expression of the transgene even in 
the absence of doxycycline (Figure 3).102  
 
 
Figure 3. Il13 expression in the absence of doxycycline in CCSP-rtTA-Il13-Tg mice. Il13 levels in 
lung homogenates from WT mice and CCSP-rtTA-Il13-Tg mice exposed to normal water, and from 
CCSP-rtTA-Il13-Tg mice exposed to doxycycline containing water (1 mg/ml dissolved in 5 % sucrose) 
determined by real-time RT-PCR. n = 6–10 mice/group. *P < 0.05 compared with WT mice.  
Scnn1b-Tg and Il13-Tg mice were intercrossed with Il13-/- mice to generate Scnn1b-Tg/Il13+/- 
and Il13-Tg/Il13+/- mice. Experimental animals were bred by intercrossing of  
Scnn1b-Tg/Il13+/- or Il13-Tg/Il13+/- mice with Il13-/- mice to obtain Il13+/-, Il13-/-,  
Scnn1b-Tg/Il13+/-, Scnn1b-Tg/Il13-/-, and Il13-Tg/Il13+/- and Il13-Tg/Il13-/- mice, respectively. 
This breeding strategy generated control groups heterozygous for the deletion of Il13, which 
are not expected to be different from wild-type mice.103 To generate Scnn1b-Tg/Il13-Tg/Il13-/- 
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mice, Scnn1b-Tg/Il13-/- mice were crossed with Il13-Tg/Il13-/- mice. Stat6-/- mice were 
backcrossed onto the C57BL/6N background (Jackson Laboratories, Bar Harbor, Me, USA). 
Mice were genotyped from tail biopsies by polymerase chain reaction (PCR) as previously 
described or as recommended by Jackson Laboratories.76,92,103,104 Mice were either studied 
at neonatal (postnatal day (PND) 5.5) or juvenile (3–4 weeks old) ages. Littermates were 
used for all experiments. Mice were housed in a specific pathogen-free animal facility with a 
standard 12 hours day/night cycle at 22°C and had free access to food and water. 
2.2 Aspergillus fumigatus instillation 
To induce allergic airway inflammation, juvenile WT and Scnn1b-Tg mice were challenged 
by repeated sensitization with Aspergillus fumigatus (Af) extract (Hollister-Stier Laboratories, 
Spokane, WA, USA) according to a previously established protocol.95 Mice were 
anesthetized with 3 % isoflurane (Baxter, Deerfield, Ill, USA) in oxygen, and 20 µl of Af  
(2 mg/ml) dissolved in 0.9 % NaCl (B. Braun, Melsungen, Germany), or equal volumes of 
vehicle (0.9 % NaCl) alone, were administered by means of intratracheal instillation every  
48 hours for a period of 1 week. All endpoint studies were performed 24 hours after the last 
Af exposure. 
2.3 Hypertonic saline treatment 
For preventive hypertonic saline (HS) study, newborn Il13-/-, Scnn1b-Tg/Il13-/-, Il13-Tg/Il13-/-, 
and Scnn1b-Tg/Il13-Tg/Il13-/- littermates were treated with 7 % HS directly after birth.  
10 % NaCl (B. Braun, Melsungen, Germany) was dissolved in double distilled (dd) H2O. 
Mice were anesthetized with 3 % isoflurane (Baxter, Deerfield, Ill, USA) in oxygen and 
treated with 7 % HS (1 µl/g body weight) by intranasal instillation 3 times per day for a 
period of 6 days.  
2.4 IL-33 instillation 
WT mice were anesthetized with 3 % isoflurane (Baxter, Deerfield, Ill, USA) in oxygen, and 
20 µl of recombinant (r)IL-33 (5 µg; R&D Systems, Minneapolis, MN, USA) dissolved in  
0.1 % bovine serum albumin (BSA) containing phosphate-buffered saline (PBS; Thermo 
Fisher Scientific, Darmstadt, Germany), or equal volumes of vehicle (0.1 % BSA in PBS) 
alone, were administered by means of intratracheal instillation every 48 hours for a period of 
1 week. Endpoint studies were performed 24 hours after the last exposure. 
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2.5 Bronchoalveolar lavage and cytokine measurements 
Juvenile mice were deeply anesthetized by intraperitoneal injection with ketamine  
(120 mg/kg) (Bremer Pharma, Warburg, Germany) and xylazine (16 mg/kg) (CP-Pharma, 
Burgdorf, Germany) and killed by exsanguination. The trachea was cannulated, the left main 
stem bronchus was ligated and right lobes were lavaged twice with sterile PBS (Thermo 
Fisher Scientific, Darmstadt, Germany) containing cOmplete Protease Inhibitor (Sigma-
Aldrich, Taufkirchen, Germany) with a volume of 0.0175 ml/g body weight, as previously 
described.95 For gene expression studies, right lobes were stored in RNAlater (Thermo 
Fisher Scientific, Darmstadt, Germany) at -80°C. For histological analysis, left lobes were 
left in 4 % buffered formalin overnight at 4°C, followed by a washing step with PBS and 
transferred to 70 % ethanol (Carl Roth, Karlsruhe, Germany) for longtime storing at 4°C. 
BAL fluid was centrifuged at 300 x g for 5 minutes at 4°C (Eppendorf, Wesseling-Berzdorf, 
Germany), the supernatant was stored at -80°C and subsequently used to determine the 
concentrations of IL-4, IL-5, and IL-13 by using the cytometric bead array enhanced 
sensitivity flex set (BD Biosciences, Heidelberg, Germany), according to the manufacturer’s 
instructions. Flow cytometry was performed with cells from BAL fluid as described in  
section 2.6. 
2.6 Flow cytometry 
For isolation of leukocytes from BAL fluid, cells were transferred to 5-ml polystyrene round-
bottom tubes (BD Biosciences, Heidelberg, Germany), 500 µl PBS and 2 ml 1.5 % 
sputolysin (Merck, Darmstatdt, Germany) diluted in nuclease-free H2O was added and 
thoroughly vortexed to separate cells from mucus. After incubation of 15 minutes at room 
temperature, cells were washed 2 times by adding fluorescence-activated cell sorting 
(FACS) buffer, containing PBS supplemented with 1 % inactivated fetal bovine serum (FBS) 
(Thermo Fisher Scientific, Darmstadt, Germany) and 0.09 % sodium azide (Sigma-Aldrich, 
Taufkirchen, Germany) and centrifuged at 300 x g for 5 minutes at 4°C. Subsequently, cells 
were resuspended in FACS buffer and total cell numbers as well as viability were assessed 
in Neubauer counting chambers (Karl Hecht, Sondheim v. d. Rhön, Germany) by using the 
trypan blue exclusion test. Cell suspension was incubated with 1 µl FcBlock (BD 
Biosciences, Heidelberg, Germany) for 5 minutes at room temperature, followed by cell 
surface staining with 50 µl master mix of specific monoclonal fluorochrome-conjugated 
antibodies (Table 1) or respective isotype control antibodies for 30 minutes at 4°C in the 
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dark. Immediately after cellular staining flow cytometry was performed using a LSRFortessa 
flow cytometer (BD Biosciences, Heidelberg, Germany). After exclusion of debris, nonviable 
cells, and doublets, data were analyzed with FACSDiva software (v8.0.1; BD Biosciences, 
Heidelberg, Germany). BAL cells were characterized as follows: CD4+ T cells (CD3+, CD4+, 
F4/80-, and CD11c-), neutrophils (CD11b+, Gr1+, CD3-, and F4/80-), eosinophils (Siglec-F+, 
CD11b+, CD11c-, Gr1-, and CD3-), airway macrophages (AMs) (Siglec-F+, CD11c+, MHCIImid, 
F4/80+, CD3-).  
Table 1. Antibody master mix for the detection of leukocytes from BAL fluid by flow cytometry. 
Antibody Clone Fluorophore Supplier Dilution 
CD3e 500A2 V500 BD Biosciences 1:50 
CD4 RM4-5 Fluorescein isothiocyanate (FITC) Thermo Fisher  1:50 
CD11b M1/70 Brilliant violet (BV) 605 Biozol* 1:100 
CD11c HL3 
Phycoerythrin (PE)- cyanine (Cy) 
Cy7 
BD Biosciences 1:200 
CD206 MR5D3 PE Bio-Rad* 1:20 
CD301 ER-MP23 Alexa Fluor 647 Bio-Rad 1:20 
F4/80 BM8 Allophycocyanin (APC)-Cy7 Biozol 1:100 
Gr1 RB-8C5 
Peridinin-chlorophyll-protein 
complex (PerCP)- Cy 5.5 
Thermo Fisher 1:50 
MHCII M5/114.15.2 eFluor 450 Thermo Fisher  1:400 
Siglec-F E50-2440 PE-CF594 BD Biosciences 1:50 
*Biozol, Eching, Germany; Bio-Rad, Dreieich, Germany 
2.7 Histology and morphometry 
2.7.1 Tissue embedding and sectioning 
Before paraffin embedding, left lobes were transversally cropped at the apical part. Tissue 
was dehydrated in embedding cassettes (Steinbrenner Laborsysteme, Wiesenbach, 
Germany) by ascending ethanol series (2 x 30 minutes 96 %, 2 x 45 minutes 100 %) (Carl 
Roth, Karlsruhe, Germany), cleared in xylene (Carl Roth, Karlsruhe, Germany) overnight, 
infiltrated with paraffin (Carl Roth, Karlsruhe, Germany) by applying vacuum for 2 hours, 
followed by 1 hour of atmospheric pressure, and finally embedded with the cropped surface 
facing downwards to ensure correct orientation of the tissue. Paraffin sections of 1.5 µm and 
5 µm thickness were prepared with a microtome (Leica Microsystems, Nussloch, Germany). 
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Left lobes were sectioned transversally at the level of the proximal intra-pulmonary main 
axial airway near the hilus. 
2.7.2 Histology 
Before staining, sections were deparaffinized 2 x 10 minutes in xylene (Carl Roth, Karlsruhe, 
Germany), rehydrated by descending alcohol series (2 x 5 minutes 100 %, 2 x 3 minutes 96 
%, 2 minutes 70 %) (Carl Roth, Karlsruhe, Germany), and finally rinsed in ddH2O.  
For mucus measurements and goblet cell counts, Alcian blue periodic acid-Schiff (AB-PAS) 
staining was performed on 5 µm and 1.5 µm sections of left lobe. Sections were immersed 
in Alcian blue solution containing 3 % acetic acid (Carl Roth, Karlsruhe, Germany),  
1 % Alcian Blue 8GX (Sigma-Aldrich, Taufkirchen, Germany), and 1 crystal of Thymol 
(Sigma-Aldrich, Taufkirchen, Germany) for 30 minutes and subsequently rinsed in tab water 
for 2 minutes. After staining with 0.5 % periodic acid solution (Sigma-Aldrich, Taufkirchen, 
Germany) for 5 minutes, sections were rinsed 3 x in ddH2O, followed by Schiff’s reagent 
(Sigma-Aldrich, Taufkirchen, Germany) for 15 minutes and 1 minute in sulfur solution 
containing 1 % 5 M HCl (Merck, Darmstadt, Germany), 0.6 % sodium metabisulfit (Sigma-
Aldrich, Taufkirchen, Germany), and subsequently rinsed in tab water. Finally, AB-PAS-
stained sections were immersed in 96 % ethanol for 1 minute, 2 x 1 minute in 100 % 
ethanol, cleared in xylene for 3 minutes, and mounted with permanent mounting medium 
(Sigma-Aldrich, Taufkirchen, Germany). 
2.7.3 Immunohistochemisty 
To localize IL-13, immunohistochemical staining was performed on formalin-fixed, paraffin-
embedded 1.5 µm lung sections of the left lobe by using a polyclonal goat anti-mouse IL-13 
antibody (R&D Systems, Minneapolis, MN, USA) at a dilution of 1:1000. Unstained and 
hydrated paraffin sections were pretreated for 10 minutes with 3 % hydrogen peroxide, 
rinsed 3 x 2 minutes in PBS, followed by antigen retrieval with Citra plus buffer (BioGenex, 
San Ramon, CA, USA) and incubation with a nonspecific protein-blocking solution 
containing animal serum (Vector Laboratories, Burlingame, CA, USA) for 30 minutes. Tissue 
sections were incubated overnight at 4°C with the primary antibody. After washing with PBS, 
slides were incubated with a biotinylated rabbit anti-goat IgG antibody as secondary 
antibody for 30 minutes at room temperature. Immunoreactivity of IL-13 was visualized with 
Vectastain Elite Kit ABC Reagent (Vector Laboratories, Burlingame, CA, USA) according to 
the manufacturer’s instructions, followed by 3, 3’-diaminobenzidine (DAB) substrate kit 
Material and Methods   
14   
(Vector Laboratories, Burlingame, CA, USA) for 3 minutes. As a negative control, each 
experiment included lung sections stained with secondary antibody only. Sections were 
counterstained with hematoxylin (Sigma-Aldrich, Taufkirchen, Germany) for 5 seconds, 
dehydrated, cleared and mounted. 
2.7.4 Morphometry 
For morphometric measurements, images were captured with an Olympus IX-71 microscope 
(Olympus, Hamburg, Germany) and analyzed by using Cell F analysis software (OSIS, 
Münster, Germany).  
Goblet cells and IL-13+ cells were determined in 1.5 µm lung sections from the left lobe 
stained with AB-PAS or anti-IL-13 antibody/DAB substrate, respectively, and identified by 
the presence of intracellular AB-PAS-positive and DAB-positive material. Numeric densities 
were quantified by counting the number of goblet cells and IL-13+ cells per millimeter of the 
basement membrane.  
Airway mucus content was determined on 5 µm AB-PAS-stained sections by using a defined 
threshold for the AB-PAS-positive material in the airway related to the area of the airway, 
which was derived from the length of the luminal membrane of the airway epithelium. This 
ratio was then normalized to the surface area per unit volume, as previously 
described.15,105,106 Semi-quantitative assessment of airway mucus obstruction was 
determined by scoring for the absence or presence of intraluminal mucus accumulation, as 
defined by AB-PAS-positive material taking up ≥ 10 % of the cross-sectional area of the 
airway lumen.91  
2.8 Laser micro-dissection 
Juvenile mice were deeply anesthetized by intraperitoneal injection with ketamine  
(120 mg/kg) (Bremer Pharma, Warburg, Germany) and xylazine (16 mg/kg) (CP-Pharma, 
Burgdorf, Germany) and killed by exsanguination. The trachea was cannulated, the left main 
stem bronchus was ligated and right lobes were inflated with tissue-tek O.C.T. compound 
(Sakura Finetek, Torrance, CA, USA) diluted in PBS (1:1). The right superior lobes were 
embedded in Peel-A-Way Embedding Molds (Polysciences Europe, Eppelheim, Germany) 
containing tissue-tek O.C.T. compound, and subsequently frozen in liquid nitrogen. Lobes 
were sectioned transversally at 10 µm thickness with a cryostat CM1950 (Leica, Wetzlar, 
Germany) and mounted on MembraneSlides 1.0 PEN (Zeiss, Jena, Germany). Airway 
epithelium was identified by light microscopy, micro-dissected and catapulted in an adhesive 
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cap of a microfuge tube (Zeiss, Göttingen, Germany) using the MicroBeam system (PALM 
Microlaser Technologies, Bernried, Germany) consisting of a 337 nm nitrogen laser 
integrated in an inverted microscope (Axiovert 200, Zeiss, Göttingen, Germany).  
2.9 Mucociliary clearance  
Mucociliary clearance was determined by measuring the elimination of fluorochrome-labeled 
Af after intratracheal instillation, as previously described.95 In brief, Af extract (Hollister-Stier 
Laboratories, Spokane, WA, USA) was labeled with Alexa Fluor 647 Microscale Protein 
Labeling Kit (Thermo Fisher Scientific, Darmstadt, Germany), according to the 
manufacturer’s instructions. By intratracheal instillation, 2.5 µg of Alexa Fluor 647-labeled Af 
dissolved in 20 µl PBS was administered in WT, Scnn1b-Tg, and Il13-Tg mice after 
anesthesia with 3 % isoflurane (Baxter, Deerfield, Ill, USA) in oxygen. Either immediately  
(t = 0) or 1 hour after instillation mice were deeply anesthetized with intraperitoneal 
injections of ketamine (120 mg/kg) (Bremer Pharma, Warburg, Germany) and xylazine  
(16 mg/kg) (CP-Pharma, Burgdorf, Germany) and sacrificed by exsanguination. Lungs and 
tracheae were excised en bloc and homogenized in 500 µl PBS with a tissue homogenizer 
(IKA, Staufen, Germany). Fluorescence intensity was measured in a plate reader (Perkin 
Elmer, Waltham, MA, USA) and the percentage of clearance after 1 hour was calculated as 
follows: (1 - Fluorescence intensity at t = 1 hour / Fluorescence intensity at t = 0) x 100. 
Baseline (t = 0) fluorescence intensity did not differ between WT, Scnn1b-Tg, and Il13-Tg 
mice. 
2.10 Ex vivo micro-computed tomography  
To visualize pulmonary alterations of the whole lung, ex vivo micro-computed tomography 
(µ-CT) imaging was performed. Lungs were fixed by vasculature perfusion as previously 
described.107 Mice were deeply anesthetized with intraperitoneal injections of ketamine 
(120 mg/kg) (Bremer Pharma, Warburg, Germany) and xylazine (16 mg/kg) (CP-Pharma, 
Burgdorf, Germany). To preserve airway mucus in its original location, tracheae of 
euthanized neonatal mice were tied to reserve the residual volume of air in the lungs, and 
no positive airway pressure was applied to inflate the lungs. The chest was opened and 
thymus and ribs were removed making the heart accessible for perfusion. The right ventricle 
was cannulated with a 22 G angiocatheter (Hospira, München, Germany) and the left atrium 
was cut for drainage. Lungs were perfused with Ringer solution (B. Braun, Melsungen, 
Germany) containing 5 % dextran 70 (Carl Roth, Karlsruhe, Germany), 0.02 % procaine 
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(Jenapharm, Jena, Germany) and 5 IU/ml heparin (Ratiopharm, Ulm, Germany) for  
15 minutes to prevent blood clotting and to ensure vasodilation for homogeneous perfusion. 
For fixation, lungs were perfused with fixative solution containing ddH2O supplemented with 
25 % polyethylene glycol (Carl Roth, Karlsruhe, Germany), 10 % ethanol (Carl Roth, 
Karlsruhe, Germany) and 3.7 % formaldehyde (AppliChem, Darmstadt, Germany) for  
30 minutes under a constant pressure of 20 cm. Lungs were removed and further processed 
using an osmium impregnation technique, as previously described.108  
Imaging of explanted lungs was performed with a Bruker SkyScan 1176 µ-CT using the 
following acquisition settings, resulting in an acquisition time of 1.75 hours: 50 kVp tube 
potential, 0.5 mm aluminum filtration, 500 µA tube current, 0.2° rotation step size over a full 
rotation of 360°, and detector pixel size of 8.65 µm (spatial resolution) applying a frame 
averaging of 5. Volume image data (897 slices of 1812×1812 pixels² each) were 
reconstructed with NRecon (v1.7.0.4; Bruker BioSpin, Rheinstetten, Germany) and analyzed 
with CTVox (v3.2.0; Bruker BioSpin) software.  
Based on µ-CT image data, atelectasis and mucus plugging were graded semi-quantitatively 
on a 0 to 2 scale (0 = no, 1 = mild, 2 = severe) for each airway segment using an adapted 
mouse airway nomenclature suggested by Thiesse et al.109 Airways in atelectatic areas were 
scaled with a score of 2 because mucus cannot be differentiated from atelectatic regions by 
µ-CT imaging.  
2.11 Murine primary tracheal epithelial cell cultures  
Mice were deeply anesthetized via intraperitoneal injection of ketamine (120 mg/kg) (Bremer 
Pharma, Warburg, Germany) and xylazine (16 mg/kg) (CP-Pharma, Burgdorf, Germany), 
killed via exsanguination and tracheae were removed. Isolation and culture of primary 
murine tracheal epithelial cells was performed according to Mayer et al.110 Tracheae of  
6–10-week-old mice were excised, cut open and transferred to collection medium containing 
DMEM/F-12 (1:1) (Thermo Fisher Scientific, Darmstadt, Germany) and 1 % Penicillin-
Streptamycin (Thermo Fisher Scientific, Darmstadt, Germany). Tracheae were washed in 
PBS, transferred to 20 ml dissociation medium containing PBS (Thermo Fisher Scientific, 
Darmstadt, Germany) supplemented with 1.4 mg/ml Protease E (Sigma-Aldrich, 
Taufkirchen, Germany), 0.1 mg/ml DNase I (Sigma-Aldrich, Taufkirchen, Germany), 72 mg 
NaHCO3, 0.1 µl FeN3O9, 0.2 µl Sodium Pyruvate (100 mM), and 0.6 % Penicillin-
Streptamycin and incubated overnight at 4°C. After incubation for 1 hour at 37°C, 5 ml heat-
inactivated FBS (Thermo Fisher Scientific, Darmstadt, Germany) was added to stop 
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enzymatic digestion. The cell suspension was filtered through a 100 µm cell strainer (Sigma-
Aldrich, Taufkirchen, Germany), centrifuged 10 minutes at 1300 rpm, resuspended in 
DMEM/F-12 (1:1) medium supplemented with heat-inactivated FBS, insulin (human 
recombinant zinc) (Thermo Fisher Scientific, Darmstadt, Germany) and primocin (InvivoGen, 
Toulouse, France) and incubated at 37°C for 2 hours to separate adherent non-epithelial 
cells (fibroblasts). Epithelial cells were seeded on collagen IV-coated (0.5 mg/ml type IV 
placenta collagen diluted in 0.2 % acetic acid (Sigma-Aldrich, Taufkirchen, Germany)) 
transwell filters (Corning, Glendale, NY, USA). On day two of culture, medium of the apical 
surface was removed to establish air-liquid interface (ALI) conditions (Figure 4) for the 




Figure 4. Murine primary tracheal epithelial cell cultures. Isolated cells were seeded and cultured 
under submerged conditions (left). After two days, air-liquid interface (ALI) conditions (right) were 
established, and substances were added to the basolateral site when cells reached confluence.  
 
After reaching confluence, cells were treated with the substances as listed in Table 2 by 
adding to the basolateral side. For pharmacological inhibition study, ALI cultures were pre-
incubated with anti-suppression of tumorigenicity 2 (St2) antibody, the myeloid differentiation 
primary-response protein 88 (MyD88) inhibitory peptide Pepinh-MYD, or the p38 MAPK 
inhibitor SB203580 as listed in Table 2, and subsequently stimulated with rIL-33 (10 ng/ml) 
for 3 hours. For the wound assay, circular wounds were made in confluent cell layer using 
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Table 2. Substances and conditions used for treatment of murine primary tracheal epithelial 
cell cultures. 
Treatment Concentration Incubation Supplier 
rIL-1α  100 ng/ml 24 h R&D systems 
rIL-4 10 ng/ml 24 h R&D systems 
rIL-9 10 ng/ml 24 h R&D systems 
rIL-13 10 ng/ml 24 h R&D systems 
rIL-33 0.025–100 ng/ml 24 h R&D systems 
rThymic stromal lymphopoietin (Tslp) 10 ng/ml 24 h R&D systems 
Aspergillus fumigatus 0.1–1 mg/ml 24 h Hollister-Stier 
Ionomycin 1 µg/ml 4 h Sigma-Aldrich 
Lipopolysaccharide (LPS) 0.001–1 µg/ml 24 h Sigma-Aldrich 
Wound assay  24 h  
Anti-St2 antibody 30 µg/ml 1 h R&D systems 
Pepinh-MYD 50 µM 6 h InvivoGen 
SB203580 20 µM 1 h InvivoGen 
 
2.12 RNA extraction and real time RT-PCR 
2.12.1 RNA extraction and RT-PCR 
Total RNA was isolated from lung tissue or from cell cultures. First, lung tissue was 
homogenized with a tissue homogenizer (IKA, Staufen, Germany) and murine primary 
tracheal epithelial cultures were washed with PBS. Total RNA was extracted by using the 
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
Total RNA from micro-dissected tissue was isolated using the RNeasy Micro Kit (Qiagen, 
Hilden, Germany). Before extraction, micro-dissected samples were incubated in the 
provided lysis buffer for 30 minutes at room temperature, centrifuged at 12000 rpm for  
5 minutes and proceeded according to the manufacturer’s protocol. The cDNA was 
synthesized by reverse transcription (RT) of 1 µg of total RNA from lung homogenate and  
10 µl total RNA from micro-dissected tissue and primary tracheal epithelial cells (Superscript 
III RT; Thermo Fisher Scientific, Darmstadt, Germany).  
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2.12.2 Real-time PCR 
Real-time PCR was performed on an Applied Biosystems 7500 Real Time PCR System 
using TaqMan universal PCR master mix and inventoried TaqMan gene expression assays 
for β-Actin (Actb) (Mm00607939_s1), Gapdh (NM_008084.2), Gob5 (Mm01320697_m1), 
Il13 (Mm00434204_m1), Il33 (Mm00505403_m1), Muc5ac (Mm01276718_m1), Muc5b 
(Mm00466391_m1), Foxa3 (Mm00484714_m1) and Spdef (Mm00600221_m1) according to 
the manufacturer’s instructions (Thermo Fisher Scientific, Darmstadt, Germany). For relative 
quantification, the relative fold changes of target gene expression were determined from the 
efficiency of the PCR reactions and the crossing point deviation between samples from the 
different genotypes in relation to WT vehicle-treated, Il13+/-, or Il13-/- mice, as appropriate, 
and normalized to the expression of the reference gene Actb (or Gapdh as for Figure 3) as 
previously described.111  
For micro-dissected airway epithelium, target sequences were preamplified before 
quantitative PCR using Platinum Taq DNA Polymerase (Thermo Fisher Scientific, 
Darmstadt, Germany) and the intron-spanning primers as listed in Table 3. 
Table 3. Sense and antisense primers used for preamplification. 
Gene  Sequence 5’ → 3’ 
Il13  sense 5’-CTG TGT CTC TCC CTC TGA CCC-3’ 
 antisense 5’-CCA GGG CTA CAC AGA ACC CG-3’ 
Il33  sense 5’-ACA CAT TGA GCA TCC AAG GAAC-3’ 
 antisense 5’-AAG AAG GCC TGT TCC GGA GG-3’ 
Actb  sense 5’-AGA TCA AGA TCA  TTG CTC CTC CT-3’ 
 antisense 5’-TGC TCC AAC CAA CTG CTG TC-3’ 
 
2.12.3 Generation of plasmid standards for real-time PCR 
For absolute quantification of Muc5ac and Muc5b transcripts, copy numbers were calculated 
using a plasmid DNA standard curve. Intron-spanning primer pairs as listed in Table 4 were 
designed for Muc5ac and Muc5b, and target sequences were amplified with Platinum Pfx 
DNA Polymerase (Thermo Fisher Scientific, Darmstadt, Germany). PCR products were 
verified by gel electrophoresis and cloned into pCR-Blunt-II-TOPO vector using the Zero 
Blunt TOPO PCR Cloning Kit (Thermo Fisher Scientific, Darmstadt, Germany) according to 
the manufacturer’s instructions. Recombinant vectors were transformed into chemically 
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competent Escherichia coli (One Shot TOP10, Thermo Fisher Scientific, Darmstadt, 
Germany) and transformations were spread on selective Luria-Bertani (LB) plates containing 
50 µg/ml kanamycin (Carl Roth, Karlsruhe, Germany) and incubated overnight at 37°C. 
Picked colonies were cultured in culture tubes (Sarstedt, Nümbrecht, Germany) in 
kanamycin supplemented LB medium overnight at 200 rpm and 37°C. DNA plasmids were 
isolated with QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions, followed by restriction digest (TatI, Thermo Fisher Scientific, 
Darmstadt, Germany) to confirm presence of inserts. After amplification with Platinum Pfx 
DNA Polymerase, a standard curve was prepared for Muc5ac and Muc5b and real-time 
PCR was performed as described above. Total copy numbers were calculated from the 
standard curve and then normalized to levels of Actb. 
Table 4. Sense and antisense primers used for amplifiction of Muc5ac and Muc5b. 
Gene  Sequence 5’ → 3’ 
Muc5ac  sense 5’-CTG GAA GGA TGC TAT CCC AAG-3’ 
 antisense 5’-GCA GCC TCC TAT GCC ATC TG-3’ 
Muc5b  sense 5’-TGG AGA ATG AGA ACT TCG CCC-3’ 
 antisense 5’-AAG TAG CCC TTG GTT TGG GG-3’ 
 
2.13 Statistics 
Data were derived from at least 3 independent experiments and were analyzed with 
SigmaPlot version 12.5 (Systat Software, Erkrath, Germany) and presented as mean  
± SEM Statistical analysis were performed with one-way ANOVA, Tukey’s post hoc test, 
Kruskal-Wallis ANOVA, Dunnʼs post hoc test, unpaired Student’s t-test, Fisher’s exact test, 
and Kaplan-Meier, as appropriate. P < 0.05 was accepted to indicate statistical significance. 
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3 Results 
3.1 Airway epithelial cells express IL-13  
Previous studies from our group demonstrated that juvenile Scnn1b-Tg mice with impaired 
MCC produce spontaneous transient type 2 airway inflammation including airway 
eosinophilia and elevated IL-13 levels that is exaggerated after allergen exposure.15,95 
Among leukocytes, ILC2 and Th2 cells were identified to provide sources of IL-13 in juvenile 
Scnn1b-Tg mice.95 During airway disease the airway epithelium serves as an effector tissue 
for IL-1323, but it also acts as a source of inflammatory mediators. If the airway epithelium 
itself produces IL-13 is not well studied. A few studies reported an IL-13 production by 
airway epithelial cells and preliminary data from our group indicated that the airway 
epithelium might contribute to the IL-13 production in Scnn1b-Tg mice.112-116 However, 
recent data are not completely solid and stimuli inducing IL-13 in airway epithelial cells are 
not well known. To study an epithelial IL-13 production, protein and mRNA expression was 
analyzed in the airway epithelium from juvenile WT and Scnn1b-Tg mice, and in vitro studies 
were performed to elucidate the underlying signaling pathway. To analyze if allergen 
exposure fosters IL-13 production in airway epithelial cells, a previously established 
Aspergillus fumigatus challenge model was used.95 
3.1.1 Type 2 airway inflammation in juvenile naïve and Af-challenged 
Scnn1b-Tg mice 
Previous studies demonstrated that impaired mucus clearance exacerbates allergen-
induced type 2 airway inflammation in juvenile Scnn1b-Tg mice.95 To study whether airway 
epithelial cells produce IL-13 and contribute to elevated IL-13 levels in allergen-induced type 
2 airway inflammation, 3–4-week-old WT and Scnn1b-Tg mice were challenged with 
intratracheal applications of the natural aeroallergen Af or vehicle alone. To characterize 
allergen-induced airway inflammation, the inflammatory cell counts and levels of the type 2 
cytokines IL-4, IL-5, and IL-13 were measured in BAL fluid by flow cytometry. In WT mice 
short-term Af treatment induced a moderate increase in macrophage and neutrophil counts 
(Figure 5A), elevated concentrations of IL-5 and IL-13 (Figure 6B, C), and no change in 
eosinophil counts or in the alternatively activated phenotype of airway macrophages (Figure 
5B, C). In unchallenged Scnn1b-Tg mice, eosinophil and CD4 T cell counts (Figure 5A), and 
IL-4, IL-5, and IL-13 levels (Figure 6) were spontaneously elevated. After Af exposure 
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airway eosinophilia and cytokine concentrations were significantly increased compared to 
vehicle-treated Scnn1b-Tg mice (Figure 5 and Figure 6).  
 
Figure 5. Spontaneous and exaggerated allergen-induced airway inflammation in juvenile 
Scnn1b-Tg mice. (A–C) Juvenile WT and Scnn1b-Tg mice were challenged with Af or vehicle alone. 
(A) Inflammatory cell counts in BAL fluid (Airway macrophages [AM]) determined by flow cytometry.  
n = 18–23 mice for each group. (B, C) Mean fluorescence intensity (MFI) of CD206
+
 (B) and CD301
+
 
(C) AM in BAL fluid. n = 15–20 mice for each group. *P < 0.05, §P < 0.01 compared to vehicle-treated 
mice of the same genotype, †P < 0.05, ‡P < 0.01 compared with mice with the same treatment but 
different genotype. 
Further, Af- and vehicle-treated Scnn1b-Tg mice exhibited alternatively activated airway 
macrophages, as shown by an up-regulated expression of CD206 and CD301 (Figure 5B, 
C) that is in line with increased IL-4 and IL-13 levels in Scnn1b-Tg mice (Figure 6). Taken 
together, these data confirm spontaneous and exaggerated allergen-induced type 2 airway 
inflammation associated with increased type 2 cytokine production in juvenile Scnn1b-Tg 
mice. 
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Figure 6. Exaggerated type 2 cytokine concentrations after allergen exposure in juvenile 
Scnn1b-Tg mice. (A–C) Juvenile WT and Scnn1b-Tg mice were challenged with Af or vehicle alone. 
IL-4 (A), IL-5 (B) and IL-13 (C) concentrations in BAL fluid measured by cytometric bead array.  
n = 9–11 mice for each group. *P < 0.05 compared with vehicle-treated mice of the same genotype, 
†P < 0.05, ‡P < 0.01, and §P < 0.001 compared to mice with the same treatment but different 
genotype. 
3.1.2 Airway epithelial cells are a cellular source of IL-13 in naïve and Af-
challenged Scnn1b-Tg mice 
To determine if epithelial cells express IL-13, immunohistochemistry was performed for the 
detection of IL-13 protein in lung sections from juvenile WT and Scnn1b-Tg mice challenged 
with Af or vehicle alone. Results were confirmed by determining Il13 transcript levels in 
micro-dissected airway epithelium. In naïve and Af-challenged WT mice, a few IL-13+ cells 
were counted (Figure 7A, B); however, Il13 transcripts were not detectable in WT mice 
(Figure 7C). In contrast, a distinct IL-13-positive staining was observed in epithelial cells 
from the conducting airways in Af- and vehicle-treated Scnn1b-Tg mice (Figure 7A, B) that 
was confirmed by Il13 levels in micro-dissected tissue (Figure 7C). After Af challenge, the 
number of IL-13+ cells and levels of Il13 transcripts tended to be increased in Scnn1b-Tg 
mice, however, this trend did not reach statistical significance. Taken together, these results 
demonstrate that airway epithelial cells are a source of IL-13, and that IL-13 production is 
increased in spontaneous and allergen-induced type 2 airway inflammation in juvenile 
Scnn1b-Tg mice.  
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Figure 7. Increased IL-13 expression in airway epithelial cells from Scnn1b-Tg mice.  
(A–C) Juvenile WT and Scnn1b-Tg mice were challenged with Af or vehicle alone.  
(A) Representative images of immunohistochemical detection of IL-13 in lung sections from juvenile 
WT and Scnn1b-Tg mice. IL-13 staining was not detected in sections incubated with secondary 
antibody only (control). Scale bars = 100 µm. (B) IL-13
+
 cells in the airway epithelium per mm of basal 
membrane (BM). n = 9–22 mice for each group. (C) Expression of Il13 transcripts in laser micro-
dissected airway epithelium from juvenile WT and Scnn1b-Tg mice determined by real-time RT-PCR. 
n = 7–11 mice for each group. *P < 0.05 compared with vehicle-treated mice of the same genotype. 
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3.1.3 IL-33 induces Il13 expression via the St2/Myd88/p38 signaling pathway 
in epithelial cells in vitro 
To identify the underlying signaling pathway of epithelial Il13 expression, well polarized 
murine primary tracheal epithelial cell cultures from WT and Scnn1b-Tg mice were used. 
Cultures were treated with different stimuli followed by Il13 transcript analysis. First, cultures 
were stimulated with recombinant (r) IL-9, rTslp, LPS and by inducing wounds in confluent 
cell layers, because these stimuli were reported to induce epithelial IL-13  
expression.112-114,116 Since airway epithelial cells bear the IL-4Rα/IL-13Rα1 receptor 
complex85,117, cultures were treated with rIL-4 and rIL-13. To test whether Af directly induces 
epithelial Il13 expression, cultures were further stimulated with Af. Under basal conditions 
and after treatment with rIL-4, rIL-9, rIL-13, rTslp, Af, LPS, or in response to the wound 
assay, Il13 was not detected in primary tracheal epithelial cells neither derived from WT nor 
from Scnn1b-Tg mice (Table 5). In immune cells, the Ca2+ ionophore ionomycin is used as a 
non-specific stimulus for experimental cytokine production.75,103,118 In vivo, IL-33 potently 
stimulates IL-13 production (e.g. by ILC2s and Th2 cells).119,120 Stimulation with ionomycin 
and rIL-33 resulted in Il13 expression in cultures from WT and Scnn1b-Tg mice (Table 5 and 
Figure 8A). 
Table 5. Stimuli tested for induction of ll13 expression in primary tracheal epithelial cell 
cultures from WT and Scnn1b-Tg mice.  







Wound assay  
 
Due to the important role of IL-33 as an epithelial-derived alarmin orchestrating type  
2 airway inflammation, the IL-33-induced epithelial IL-13 production was investigated.  
Dose-dependent induction of Il13 revealed an effective concentration of 10 ng/ml for further 
experiments (Figure 8B). The transcription factor Stat6 is known to promote transcriptional 
activation of Il13 in Th2 cells.121,122 In primary tracheal epithelial cell cultures, Il13 expression 
in response to rIL-33 was not impeded by genetic deletion of Stat6 (Figure 8C) 
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demonstrating a Stat6 independent mechanism. Another pathway in immune cells signals 
via the IL-33 receptor St2, Myd88, and MAPK.119 It was shown that tracheal epithelial cells 
from both genotypes express St2 (Figure 8D). IL-33-mediated Il13 expression was blocked 
by using an anti-St2 antibody, the MyD88 inhibitory peptide Pepinh-MYD, or the p38 MAPK 
inhibitor SB203580 (Figure 8E). Collectively, these data show that epithelial IL-13 production 
is induced in response to IL-33 via the St2/Myd88/p38 signaling pathway.  
 
 
Figure 8. IL-33 triggers epithelial Il13 expression via St2/Myd88/p38 signaling in vitro.  
(A–E) Primary tracheal epithelial cells were cultured under ALI conditions. mRNA expression was 
analyzed under basal conditions and after stimulation by the basolateral side. (A) Induction of Il13 
expression in murine primary tracheal epithelial cells derived from WT and Scnn1b-Tg mice by rIL-33 
and ionomycin. (B) Dose-dependent induction of Il13 expression in WT cultures in response to rIL-33. 
(C) Induction of Il13 expression in response to rIL-33 in murine primary tracheal epithelial cells 
derived from Stat6
-/-
 mice. (D) mRNA expression levels of the IL-33 recpetor St2 in WT and  
Scnn1b-Tg cell cultures. (E) Effects of the IL-33/St2 signaling pathway on Il13 expression in primary 
tracheal epithelial cells of WT mice. n = 3–10 for each group. *P < 0.05 compared with vehicle-treated 
cultures of the same genotype; †P < 0.05 and ‡P < 0.01 compared with rIL-33-treated WT cultures. 
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3.1.4 In vivo role of IL-33 on epithelial IL-13 production 
Based on these in vitro results, it was hypothesized that IL-33 might also be a stimulating 
factor in vivo. First, the transcript levels of Il33 in lung homogenates and micro-dissected 
airway epithelium from naïve and Af-challenged WT and Scnn1b-Tg mice were determined. 
Il33 transcripts were detectable in lung tissue and micro-dissected airway epithelia from WT 
mice independent of Af treatment (Figure 9). In Scnn1b-Tg mice, Il33 expression in both 
tissues was significantly increased compared to WT mice (Figure 9). After Af challenge, Il33 
transcripts tended to be increased in lung homogenates from Scnn1b-Tg mice (Figure 9A). 
In airway epithelial tissue Il33 levels did not differ between naïve and challenged Scnn1b-Tg 
mice (Figure 9B).  
 
 
Figure 9. Increased Il33 expression in juvenile Scnn1b-Tg mice. (A, B) Juvenile WT and  
Scnn1b-Tg mice were challenged with Af or vehicle alone. Expression of Il33 transcripts in lung 
homogenates (A) and laser micro-dissected airway epithelium (B) from juvenile WT and Scnn1b-Tg 
mice measured by real-time RT-PCR. n = 7–11 mice for each group. *P < 0.05 compared with 
vehicle-treated mice of the same genotype. 
 
As a proof of concept, it was tested if exogenous IL-33 induces epithelial IL-13 in vivo. 
Whilst vehicle-treated WT mice did not show positive anti-IL-13 staining, WT mice treated 
with rIL-33 revealed a distinct epithelial anti-IL-13-positive staining (Figure 10). 
Taken together, under conditions of type 2 inflammation Scnn1b-Tg mice express increased 
levels of IL-33 by airway epithelial cells, and IL-33 is sufficient to induce epithelial IL-13 
production in vivo. 
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Figure 10. Epithelial IL-13 expression in response to exogenous IL-33 in WT mice. 
Immunohistochemical detection of IL-13 in lung sections from juvenile WT mice treated with rIL-33 or 
vehicle alone. Scale bars = 100 µm. n = 3 mice for each group 
 
3.2 Relative contributions of IL-13-induced mucin hypersecretion 
and airway surface dehydration to airway mucus obstruction 
Under conditions of type 2 airway inflammation where IL-13 induces GCM and mucin 
expression, it is not known to what extent airway surface dehydration and mucin 
hypersecretion affects airway mucus plugging. Therefore, the in vivo pathogenesis of airway 
mucus obstruction primarily triggered by airway surface dehydration or mainly induced by  
IL-13-induced mucin hypersecretion was studied. First, it was investigated if airway 
dehydration is sufficient to cause mucus plugging in the absence of the mucin-inducing 
cytokine IL-13 by using Scnn1b-Tg mice with genetic deletion of IL-13 (Scnn1b-Tg/Il13-/-). 
Second, phenotypes of Scnn1b-Tg mice were compared to mice with overexpression of  
IL-13 (Il13-Tg) enabling an evaluation of the relative contributions of airway surface 
dehydration and IL-13-induced mucin hypersecretion to airway mucus obstruction. Third, the 
expression of IL-13 exclusively in the airway epithelium (Il13-Tg/Il13-/-) allows conclusions on 
the impact of epithelium-mediated IL-13 on mucus plugging. Mice were studied at juvenile 
ages, because a spontaneous type 2 airway inflammation with increased IL-13 production 
and a most severe mucus plugging was demonstrated in Scnn1b-Tg mice at this age.15,95 
Finally, Scnn1b-Tg/Il13-/- and Il13-Tg/Il13-/- mice were crossed to evaluate the combined 
effects of airway surface dehydration and IL-13-mediated mucin hypersecretion.  
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3.2.1 Airway mucus obstruction is more severe in Scnn1b-Tg mice with 
airway surface dehydration than in mice with IL-13-mediated mucin 
hypersecretion 
To compare the muco-obstructive phenotype caused by airway surface dehydration and by 
IL-13-induced mucin hypersecretion, goblet cell numbers and airway mucus plugging of 
main axial airways were analyzed in juvenile Il13+/-, Il13-/-, Scnn1b-Tg/Il13+/-,  
Scnn1b-Tg/Il13-/-, Il13-Tg/Il13+/-, and Il13-Tg/Il13-/- mice. Neither goblet cells nor mucus were 
observed in the airways from Il13+/- and Il13-/- mice (Figure 11 and Figure 12). Airways of 
Scnn1b-Tg/Il13+/- mice showed elevated goblet cell numbers and mucus plugging compared 
to Il13+/- mice. The lack of IL-13 in juvenile Scnn1b-Tg mice significantly reduced goblet cell 
numbers that were similar to that in Il13-/- mice (Figure 12A). However, mucus plugging was 
still present and as severe as in Scnn1b-Tg/Il13+/- mice (Figure 12B, C). Overexpression of 
IL-13 induced strong GCM, consistent with published data76, and mucus accumulation in 
Il13-Tg/Il13+/- and Il13-Tg/Il13-/- mice (Figure 11 and Figure 12). Goblet cell numbers and 




Figure 11. IL-13-(in)dependent mucus accumulation in mouse models that mimic muco-













 mice. Scale 
bars = 100 µm. 
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When compared to Scnn1b-Tg/Il13+/- mice, the amount of airway mucus was 3-fold lower in 
Il13-Tg/Il13+/- mice (Figure 12A, B), although the number of goblet cells was 3-fold increased 
in IL-13-overexpressing mice. Further, airway mucus obstruction was only observed in 45 % 
of Il13-Tg/Il13+/- and Il13-Tg/Il13-/- mice, whereas in > 90 % of Scnn1b-Tg/Il13+/- and  
Scnn1b-Tg/Il13-/- mice airways were obstructed (Figure 12C). Collectively, it was shown that 
lack of IL-13 abrogates GCM, but has no effect on mucus plugging in juvenile Scnn1b-Tg 
mice. Further, the data demonstrate that epithelial overexpression of IL-13 causes less 
severe airway mucus obstruction than under conditions of airway dehydration.   
 
 
Figure 12. Mucus obstruction is more severe in Scnn1b-Tg mice than in Il13-Tg mice. Number 
of goblet cells per mm basal membrane (BM) (A), airway mucus content quantified from the AB-PAS-
positive material in the airway lumen (B), and semi-quantitative analysis of % mice showing airway 













 mice. n = 10–21 mice per genotype. *P < 0.05 vs. Il13
+/-
, §P < 0.05 vs. Il13
-/-
, †P < 0.05 
vs. Scnn1b-Tg/Il13
+/-
, ‡P < 0.05 vs. Scnn1b-Tg/Il13
-/-
. 
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3.2.2 IL-13 regulates Muc5ac and Muc5b expression  
Recent studies demonstrated that IL-13 mediates mucin gene expression, in particular that 
of Muc5ac76,77, amongst others via Gob5, which serves as a goblet cell marker (Figure 2).65 
To determine how IL-13 affects mucin expression in the studied mouse models and to 
investigate whether the severity in mucus obstruction was due to different mucin expression 
levels, relative transcript levels of Gob5, Muc5ac and Muc5b were measured in lung 
homogenates from juvenile Il13+/-, Il13-/-, Scnn1b-Tg/Il13+/-, Scnn1b-Tg/Il13-/-, Il13-Tg/Il13+/-, 
and Il13-Tg/Il13-/- mice. In Il13-/- mice, a trend towards a reduced expression of all 3 genes 
compared to Il13+/- mice was observed (Figure 13).  
 
 
Figure 13. IL-13 drives Muc5ac and Muc5b expression in juvenile Scnn1b-Tg and Il13-Tg mice. 













 mice determined by real-
time RT-PCR. n = 10–16 mice per genotype. *P < 0.05 vs. Il13
+/-
, §P < 0.05 vs. Il13
-/-
, †P < 0.05 vs. 
Scnn1b-Tg/Il13
+/-
, ‡P < 0.05 vs. Scnn1b-Tg/Il13
-/-
. 
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Increased levels of Gob5 and Muc5ac in Scnn1b-Tg/Il13+/- mice were significantly abrogated 
by deletion of IL-13 (Figure 13A, B). Consistent with the high number of goblet cells and 
previous reports77, expression of Gob5 and Muc5ac was strongly increased in IL-13-
overexpressing mice compared to Il13+/- and Il13-/- mice (Figure 13A, B). When compared to 
Scnn1b-Tg/Il13+/- mice, Il13-Tg/Il13+/- mice displayed a 6-fold elevated Muc5ac expression. 
Further, an IL-13-dependent Muc5b expression was observed. Muc5b levels tended to be 
reduced in Scnn1b-Tg/Il13-/- and Il13-/- mice in comparison to mice sufficient for IL-13, and 
were significantly increased in Il13-Tg/Il13+/- and Il13-Tg/Il13-/- mice compared to Il13+/- and 
Il13-/- mice (Figure 13C). In mice expressing IL-13 exclusively in epithelial cells, all 3 genes 
tended to be reduced compared to Il13-Tg/Il13+/- mice (Figure 13).  
Next, relative expressions of Spdef and Foxa3 were quantified in lung homogenates. These 
transcription factors are involved in the down-stream signaling pathway of IL-13-mediated 
mucin expression and goblet cell differentiation (Figure 2).80,86 Levels of Spdef and Foxa3 
did not change between Scnn1b-Tg/Il13+/-, Scnn1b-Tg/Il13-/-, Il13+/-, and Il13-/- mice (Figure 
14). In Il13-Tg/Il13+/- and Il13-Tg/Il13-/- mice, expression of both transcription factors was 
highly elevated to a similar level and increased compared to all other genotypes, as 
appropriate (Figure 14).  
 
 
Figure 14. Increased Spdef and Foxa3 expression in Il13-Tg mice but not in Scnn1b-Tg mice. 













 mice measured by real-time  
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+/-
, §P < 0.05 vs. Il13
-/-
, †P < 0.05 vs. 
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In summary, these results show that severe mucus plugging persists in Scnn1b-Tg/Il13-/- 
mice although deletion of IL-13 diminishes Muc5ac and Muc5b expression, and that Muc5ac 
levels are highly upregulated in IL-13 overexpressing mice compared to Scnn1b-Tg mice. 
Further, these data indicate that IL-13 not only regulates Muc5ac but also Muc5b 
expression. 
3.2.3 Airway surface dehydration but not IL-13-mediated mucin 
hypersecretion impairs mucociliary transport 
So far, the obtained data demonstrated that IL-13-induced mucin hypersecretion causes 
less severe mucus obstruction than airway surface dehydration in Scnn1b-Tg mice with 
mucus plugging persisting even in the absence of mucin hypersecretion. To test if these 
observations are due to differences in the ability to clear mucus, the mucociliary transport 
efficiency was determined. Fluorochrome-labeled allergen was instilled intratracheally in 
juvenile WT, Scnn1b-Tg, and Il13-Tg mice and allergen clearance of the whole lung was 
measured. Consistent with previously published data by Fritzsching et al.95, Scnn1b-Tg mice 
displayed a mean mucociliary transport efficiency of 57 % after 1 hour, which was 
significantly reduced compared to WT mice with a mean efficiency of 74 % (Figure 15). In 
contrast, in Il13-Tg mice mucociliary transport was not impaired and similar as in WT mice, 
but significantly increased compared to Scnn1b-Tg mice (Figure 15). These data 
demonstrate that mucociliary transport is impaired in Scnn1b-Tg mice, whereas IL-13-
induced mucin hypersecretion does not affect mucociliary transport.   
 
 
Figure 15. Mucociliary transport is reduced in Scnn1b-Tg mice but not in Il13-Tg mice. 
Mucociliary transport determined by the clearance efficiency of fluorochrome-labeled allergen 1 hour 
after intratracheal instillation in juvenile WT, Scnn1b-Tg, and Il13-Tg mice. n = 11–18 mice per 
genotype. *P < 0.05 vs. WT, §P < 0.05 vs. Scnn1b-Tg. 
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3.2.4 Eosinophilic and neutrophilc inflammation in Scnn1b-Tg and Il13-Tg 
mice  
To compare the inflammatory phenotypes of the studied mouse models and thereby 
assessing the role of IL-13, eosinophil and neutrophil numbers were measured in BAL fluid 
by flow cytometry in juvenile Il13+/-, Il13-/-, Scnn1b-Tg/Il13+/-, Scnn1b-Tg/Il13-/-, Il13-Tg/Il13+/-, 
and Il13-Tg/Il13-/- mice. Eosinophils and neutrophils were rarely detected in juvenile Il13+/- 
and Il13-/- mice, whereas both inflammatory cell types were significantly increased in juvenile 
Scnn1b-Tg/Il13+/- (Figure 16). Lack of IL-13 in Scnn1b-Tg mice caused a trend towards 
reduced eosinophil and increased neutrophil numbers compared to Scnn1b-Tg/Il13+/- mice 
(Figure 16A). Eosinophil and neutrophil counts remained significantly elevated in  
Scnn1b-Tg/Il13-/- mice compared to Il13-/- mice. As reported recently77,123, significantly 
increased eosinophil and neutrophil counts were observed in Il13-Tg/Il13+/- and Il13-Tg/Il13-/- 
mice compared to Il13+/- and Il13-/- mice, respectively. Exclusive expression of IL-13 in the 
airway epithelium seemed to reduce eosinophilic inflammation in Il13-Tg/Il13-/-, but this did 
not reach statistical significance (Figure 16A). With regard to the comparison of Scnn1b-Tg 
and Il13-Tg mice, eosinophils were increased to a similar level in both mouse models and 
neutrophils tended to be elevated in Scnn1b-Tg mice (Figure 16).  
 
 
Figure 16. Eosinophilc and neutrophilc inflammation in Scnn1b-Tg and Il13-Tg mice. 













 mice determined by flow cytometry. n = 21–38 mice 
per genotype. *P < 0.05 vs. Il13
+/-
, §P < 0.05 vs. Il13
-/-
. 
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In summary, these data show that in the absence of IL-13 eosinophilic inflammation persists 
in juvenile Scnn1b-Tg mice. It was demonstrated that Scnn1b-Tg and Il13-Tg mice reveal 
eosinophilic and neutrophilc infiltration.  
3.2.5 IL-13-induced mucin hypersecretion in Scnn1b-Tg mice causes 
neonatal mortality due to severe airway mucus plugging 
To test combined effects of airway surface dehydration and IL-13-mediated mucin 
hypersecretion, both mouse models were crossed to generate Scnn1b-Tg/Il13-Tg/Il13-/- 
mice. First, the survival and growth of Scnn1b-Tg/Il13-Tg/Il13-/- mice and Il13-/-,  
Scnn1b-Tg/Il13-/-, Il13-Tg/Il13-/- littermates was monitored. All Scnn1b-Tg/Il13-Tg/Il13-/- mice 
died before PND6 (Figure 17A). Accordingly, a significant reduction in body weight on PND4 
and PND5 was observed in Scnn1b-Tg/Il13-Tg/Il13-/- mice compared with Il13-/- littermates, 
whereas growth curves of Scnn1b-Tg/Il13-/- and Il13-Tg/Il13-/- mice did not differ from  
Il13-/- mice (Figure 17B). 
 
 
Figure 17. Neonatal death of Scnn1b-Tg/Il13-Tg/Il13
-/-









 littermates. n = 8–34 
mice/genotype. *P < 0.0001 vs. Scnn1b-Tg/Il13-Tg/Il13
-/-
, ‡P < 0.05 vs. Il13
-/-
. 
To determine the cause of neonatal mortality, goblet cell counts and airway mucus content 
were analyzed in airway sections from Il13-/-, Scnn1b-Tg/Il13-/-, Il13-Tg/Il13-/-, and Scnn1b-
Tg/Il13-Tg/Il13-/- mice on PND5.5. The number of goblet cells was elevated to a similar level 
in Il13-Tg/Il13-/- and Scnn1b-Tg/Il13-Tg/Il13-/- mice, whereas goblet cells were absent in 
airways from Il13-/- and Scnn1b-Tg/Il13-/- mice (Figure 18A, B). In contrast to juvenile mice 
(Figure 12), mucus obstruction was not different in neonatal  
Scnn1b-Tg/Il13-/- mice compared to Il13-Tg/Il13-/- mice (Figure 18C, D). In  
Scnn1b-Tg/Il13-Tg/Il13-/- mice, the airway mucus content was 3- to 4-fold increased 
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compared to Il13-Tg/Il13-/- and Scnn1b-Tg/Il13-/- mice. Airway mucus accumulation was 
observed in 40 % of Scnn1b-Tg/Il13-Tg/Il13-/- mice, but only in 9 % and 18 % of neonatal 
Scnn1b-Tg/Il13-/- and Il13-Tg/Il13-/- mice, respectively (Figure 18D).  
 
 
Figure 18. Severe airway mucus obstruction in airways of neonatal Scnn1b-Tg/Il13-Tg/Il13
-/-
 









 littermates. Scale bars = 100 µm. 
Number of goblet cells per mm basal membrane (BM) (B), airway mucus content quantified from the 
AB-PAS-positive material in the airway lumen (C), and semi-quantitative analysis of % mice showing 






, and  
Scnn1b-Tg/Il13-Tg/Il13
-/-
 mice. n = 10–12 mice per genotype. *P < 0.05 vs. Il13
-/-
, §P < 0.05 vs. 
Scnn1b-Tg/Il13
-/-
, †P < 0.05 vs. Il13-Tg/Il13
-/-
. 
Next, ex vivo µ-CT measurements we performed to visualize morphological alterations of 
the whole lung. Semi-quantitative analysis of all airways revealed mucus accumulation in 
neonatal Scnn1b-Tg/Il13-/-, Il13-Tg/Il13-/-, and Scnn1b-Tg/Il13-Tg/Il13-/- mice (Figure 19A, B).  
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Figure 19. Severe mucus plugging and atelectasis in neonatal Scnn1b-Tg/Il13-Tg/Il13
-/-
 mice 









mice. Scale bars = 1 
mm. CL, cardiac lobe; LL, left lobe; RLL, right lower lobe; RUL, right upper lobe. Mucus plugging 
(white arrows) (B) and atelectasis (yellow arrows, yellow framed areas) (C)  were determined by 









mice. Asterisks indicate blood vessels, triangles 
indicate airways.  n = 8–11 mice per genotype. *P < 0.001 vs. Il13
-/-
, §P < 0.001 vs. Scnn1b-Tg/Il13
-/-
, 
†P < 0.001 vs. Il13-Tg/Il13
-/-
.  
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In Il13-Tg/Il13-/- mice, the µ-CT-based mucus score was at its lowest level when compared 
to Il13-/- mice, and significantly reduced compared to Scnn1b-Tg/Il13-/- mice (Figure 19B). In 
Scnn1b-Tg/Il13-Tg/Il13-/- mice, the score was 3–5-fold increased in comparison to  
Scnn1b-Tg/Il13-/- and Il13-Tg/Il13-/- mice, respectively (Figure 19B). Complete occlusion of 
airways by mucus plugs can cause atelectasis that is the collapse of the lung parenchyma. 
Atelectatic areas were absent in Il13-/- mice (Figure 19C), but were detected in  
Scnn1b-Tg/Il13-/- and Il13-Tg/Il13-/- mice to a similar level. In line with severe mucus 
obstruction, the atelectasis score was significantly increased in Scnn1b-Tg/Il13-Tg/Il13-/- 
mice (Figure 19C). Taken together, these data demonstrate that combined effects of airway 
surface dehydration and IL-13-mediated mucin hypersecretion lead to lethal pulmonary 
alterations including severe airway mucus obstruction and serious atelectasis.  
3.2.6 Increased Muc5ac and Muc5b expression in Scnn1b-Tg/Il13-Tg/Il13-/- 
mice 
To clarify if the lethal mucus obstruction in Scnn1b-Tg/Il13-Tg/Il13-/- mice is driven by an 
exaggerated mucin expression, and to investigate if differences in Muc5ac and Muc5b 
content might contribute, expression levels of Gob5, Muc5ac, and Muc5b were determined 
in lung homogenates from neonatal Il13-/-, Scnn1b-Tg/Il13-/-, Il13-Tg/Il13-/-, and  
Scnn1b-Tg/Il13-Tg/Il13-/- mice. When compared to Il13-/- mice, relative Gob5, Muc5ac, and 
Muc5b levels were not different in neonatal Scnn1b-Tg/Il13-/- mice (Figure 20A–C). In 
contrast, in Il13-Tg/Il13-/- and Scnn1b-Tg/Il13-Tg/Il13-/- mice highly increased expression 
levels for Gob5 and both mucins were observed, with a >25-fold increase of Mu5cac 
expression compared to Scnn1b-Tg/Il13-/- mice (Figure 20 A–C). Transcript levels did not 
differ between Il13-Tg/Il13-/- and Scnn1b-Tg/Il13-Tg/Il13-/- mice.  
Absolute quantification of Muc5ac and Muc5b copy numbers revealed a similar pattern as 
observed for relative expression levels. Muc5ac and Muc5b copy numbers were significantly 
increased to a similar level in Il13-Tg/Il13-/- and Scnn1b-Tg/Il13-Tg/Il13-/- mice when 
compared to Il13-/- and Scnn1b-Tg/Il13-/- mice (Figure 20D, E). The predominant mucin in all 
genotypes was Muc5b (Figure 20E), but in Il13-Tg/Il13-/- and Scnn1b-Tg/Il13-Tg/Il13-/- mice 
Muc5ac copy numbers were highly increased (Figure 20D). The Muc5ac/Muc5b ratio 
reflects that Muc5ac expression relative to Muc5b is low in Scnn1b-Tg/Il13-/- mice, whereas 
a high Muc5ac expression relative to Muc5b was observed in Il13-/-, Il13-Tg/Il13-/- and 
Scnn1b-Tg/Il13-Tg/Il13-/- mice (Figure 20F). Collectively, these data demonstrate that total 
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mucin expression is not further exaggerated and that both Muc5ac and Muc5b are highly 
upregulated in neonatal Scnn1b-Tg/Il13-Tg/Il13-/- mice.  
 
 





 mice. (A–C) Relative expression levels of Gob5 (A), Muc5ac (B), and Muc5b (C); 
(D, E) copy numbers of Muc5ac (D) and Muc5b (E), and ratio of Mu5ac/Muc5b copy numbers (F) in 
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3.2.7 Hypertonic saline treatment does not prevent early mortality of  
Scnn1b-Tg/Il13-Tg/Il13-/- mice 
Previous studies demonstrated that preventive treatment with 7 % hypertonic saline (HS) 
improves airway surface dehydration and reduces the mortality of Scnn1b-Tg mice.124 To 
test if improvement of airway surface hydration has benefits on the survival of  
Scnn1b-Tg/Il13-Tg/Il13-/- mice, Il13-/-, Scnn1b-Tg/Il13-/-, Il13-Tg/Il13-/-, and Scnn1b-Tg/Il13-
Tg/Il13-/- mice were treated from the first day of life with intranasal instillation of 7 % HS. This 
treatment did not rescue Scnn1b-Tg/Il13-Tg/Il13-/- mice from neonatal mortality (Figure 21). 
This indicates that improvement of airway surface hydration alone is not sufficient to 
circumvent early severe mucus obstruction and associated mortality in mice with airway 
dehydration and IL-13-induced mucin hypersecretion.  
 
 
Figure 21. Treatment with 7 % HS does not rescue Scnn1b-Tg/Il13-Tg/Il13
-/-
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4 Discussion 
The airway epithelium and the mucus layer provide the first line of defense against 
environmental pathogens, irritants, toxicants, and allergens through effective MCC and 
initiation of inflammatory responses at the airway surface. In chronic airway diseases 
associated with mucus accumulation, such as CF, COPD and asthma, epithelial dysfunction 
directly affects mucus properties either through an overproduction of mucins, or an epithelial 
ion transport dysfunction resulting in airway dehydration.125 Reasons can be intrinsic due to 
a genetic disorder as in CF, environmental and/or inflammatory stimuli as in COPD and 
asthma. Reduced MCC associated with airway mucus accumulation and chronic airway 
inflammation are key features that promote airway mucus obstruction in these diseases.  
IL-13 is an important mediator in type-2 inflammation and causes mucin hypersecretion, but 
its cellular sources and the role of IL-13-mediated mucin hypersecretion in muco-obstructed 
airways are poorly understood. In this study, the airway epithelium’s potential to produce  
IL-13 was analyzed. Further, the relative and combined effects of airway surface 
dehydration and IL-13-mediated mucin hypersecretion in the pathogenesis of airway mucus 
obstruction were investigated.  
4.1 Airway epithelial cells contribute to IL-13 production in mice 
with muco-obstructive lung disease 
IL-13 plays a crucial role in muco-obstructive airway diseases due to its effects on airway 
epithelial cells.76,77,88,90 So far it is mainly believed that IL-13 is released by immune cells, 
such as ILC2 and Th2 cells. A few studies reported an IL-13 production by airway epithelial 
cells and preliminary studies from our group also suggested an epithelial IL-13 synthesis in 
juvenile Scnn1b-Tg mice with muco-obstructive lung disease. Therefore, an IL-13 production 
by airway epithelial cells was studied by analyzing protein and transcript levels, by 
investigating stimuli and signaling pathways, and by determining the impact on the in vivo 
pathogenesis of airway mucus obstruction.  
Previous studies demonstrated that Scnn1b-Tg mice develop a spontaneous type 2-biased 
inflammatory response including elevated levels of IL-13 at juvenile ages.15 To study an 
epithelial IL-13 production in juvenile WT and Scnn1b-Tg mice, spontaneous type 2 airway 
inflammation in juvenile Scnn1b-Tg mice was first confirmed. This was demonstrated by 
alternatively activated airway macrophages and increased numbers of eosinophils as well 
Discussion   
42   
as elevated concentrations of IL-4, IL-5, and IL-13 in Scnn1b-Tg mice (Figure 5 and Figure 
6). To elucidate the impact of allergen exposure on IL-13 expression, juvenile WT and 
Scnn1b-Tg mice were exposed to the natural aeroallergen Af to induce allergic airway 
inflammation. An exaggerated type 2 immune response including increased IL-13 levels was 
observed after Af challenge in juvenile Scnn1b-Tg mice (Figure 5 and Figure 6). This 
observation is consistent with previously published data from our group using a house dust 
mite challenge model and can be ascribed to mucociliary dysfunction causing an impaired 
clearance of inhaled allergens.95  
Immunohistochemical studies on human lung tissue sections by Hocke et al. and Park et al. 
indicated that bronchial epithelium and epithelial cells in bronchial glands from patients 
suffering from idiopathic pulmonary fibrosis or lung cancer, respectively, provide a source of 
IL-13.115,116 By using immunohistochemistry, IL-13 was detected in a few airway epithelial 
cells from WT mice. In contrast, increased IL-13 protein expression was readily detected in 
airway epithelial cells from naïve juvenile Scnn1b-Tg mice. This finding was confirmed in 
laser micro-dissected airway epithelium on mRNA level revealing Il13 expression in naïve 
juvenile Scnn1b-Tg mice (Figure 7). These data, for the first time, demonstrate an IL-13 
production by airway epithelial cells in muco-obstructive lung disease.  
Through recognition by Toll-like receptors (TLRs) Af activates airway epithelial cells126, and 
Af-derived proteases were shown to contribute to type 2 inflammation127 and to disrupt 
epithelial integrity leading to cytokine secretion.128 In immune cells, allergens derived from Af 
are presented by antigen presenting cells to T cells.70, and Af-specific Th2 cells were 
measured in patients with ABPA, allergic asthma, and CF.70 In this study, total IL-13 
concentration was highly upregulated in response to Af challenge (Figure 6), but in the 
airway epithelium the number of IL-13+ cells and Il13 levels were only slightly increased in 
Scnn1b-Tg mice after allergen exposure (Figure 7). Considering that Fritzsching et al. 
recently demonstrated an exaggerated number of IL-13+ T cells in lungs of Af-challenged 
Scnn1b-Tg mice95, these data indicate that exaggerated IL-13 levels in response to Af may 
be mainly produced by immune cells rather than airway epithelial cells in Scnn1b-Tg mice. 
To assess the impact of epithelial-derived IL-13 on the in vivo pathogenesis of airway mucus 
obstruction, mice with (over)expression of IL-13 exclusively in the airway epithelium  
(Il13-Tg/Il13-/-) were studied. Il13-Tg/Il13-/- mice revealed strong GCM, increased mucin 
expression, airway mucus plugging, and increased eosinophil and neutrophil numbers 
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compared to Il13-/- mice (Figure 12, Figure 13, and Figure 16). When compared to  
Il13-Tg/Il13+/- mice, mucin expression levels and eosinophil counts tended to be reduced in 
Il13-Tg/Il13-/- mice. This might be due to a higher IL-13 concentration in Il13-Tg/Il13+/- mice 
with immune cells contributing to IL-13 secretion. These data indicate that epithelial IL-13 
contributes to the muco-obstructive phenotype including mucus plugging and airway 
inflammation. However, transgenic overexpression may cause a rather non-physiological 
situation with constitutively high concentrations of IL-13.  
4.2 Epithelial IL-13 production is mediated by IL-33 via the 
St2/Myd88/p38 signaling pathway 
To investigate factors responsible for epithelial IL-13 expression, in vitro studies using 
murine primary tracheal epithelial cell cultures from WT and Scnn1b-Tg mice were 
performed in the presence of various stimuli being reported to induce IL-13. In a rat model, it 
was shown that LPS induces epithelial IL-13 expression.116 Temann et al. detected Il13 in 
epithelial cells by in situ hybridization in IL-9-overexpressing mice in the absence of 
functional T cells.113 TSLP and mechanical injury induced IL-13 production in human 
epithelial cell cultures.112,114 However, in this study neither LPS, rIL-9, rTslp stimulation or 
mechanical injury induced Il13 expression by primary epithelial cell cultures (Table 5). 
Stimulation with rIL-4 and rIL-13 did also not induce Il13 expression suggesting no positive 
feedback loop via the IL-4Rα/IL-13Rα1 receptor. Moreover, Af treatment did not stimulate 
Il13 expression further supporting the hypothesis that Af does not directly affect epithelial  
IL-13 expression.  
Upon activation (e.g. by allergens), airway epithelial cells release pre-stored alarmins, such 
as IL-33, which recruits and/or activates amongst other immune cells dendritic cells, ILC2, 
and Th2 cells.129 Interestingly, rIL-33 treatment induced expression of Il13 in primary 
tracheal epithelial cell cultures from WT and Scnn1b-Tg mice (Figure 8). This suggests 
similar mechanisms in immune cells and epithelial cells. To identify the underlying signaling 
pathway, first, the role of Stat6 was studied, which is involved in Il13 expression in Th2 
cells.121,122 The lack of Stat6 in primary tracheal epithelial cultures did not abrogate Il13 
expression after rIL-33 treatment (Figure 8), which is consistent with a recent study in 
intestinal epithelium reporting Stat6-independent Il13 expression in response to IL-33.130 
Second, the St2 receptor complex mediated pathway was elaborated, which was shown to 
drive IL-33-induced type 2 cytokine production in ILC2 and Th2 cells.129,131 Consistent with 
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previous studies by Yagami et al. and Traister et al., it was confirmed that primary tracheal 
epithelial cells express the IL-33 receptor St2.132,133 Levels of St2 did not differ between 
genotypes (Figure 8) suggesting that airway epithelial cells from WT and Scnn1b-Tg mice 
have the same potential to respond to IL-33. This might explain why Il13 expression was 
similar in cultures from WT and Scnn1b-Tg mice. An anti-St2 antibody and inhibitors against 
Myd88 and p38 MAPK in the presence of IL-33 were used to interfere the reported signaling 
pathway. Blocking only the St2 receptor or inhibiting either Myd88 or p38 MAPK impeded  
IL-33-induced Il13 expression in primary tracheal epithelial cultures (Figure 8). These data, 
for the first time, show that Il13 expression in airway epithelial cells is induced by IL-33 and 
mediated by St2/Myd88/p38 signaling. However, these data do not exclude an involvement 
of other MAPK, such as signal-regulated kinase (ERK) and JUN N-terminal kinase (JNK), 
which become also activated by this pathway.119 p38 MAPK was identified as the central 
target of IL-33-mediated cytokine production in human memory Th2 cells and murine 
peripheral blood mononuclear cells131,134, whereas ERK was required in a human bronchial 
epithelial cell line. Inhibition of ERK or JNK might also block IL-33/St2-mediated Il13 
expression. A schematic overview of the IL-33-induced signaling pathway leading to IL-13 
production is shown in Figure 22. 
IL-33 is constitutively expressed and stored as a nuclear protein in various cell types 
especially of barrier tissues.120 Hence, it is conclusive that Il33 transcripts were readily 
detected in tissues from WT mice. Expression levels of Il33 were significantly increased in 
Scnn1b-Tg mice compared to WT mice (Figure 9). This is in line with previous reports linking 
increased epithelial IL-33 levels to CF135,136, COPD137, and asthma.138,139 Inflammation, 
infections, mechanical stress, and necrosis were shown to induce IL-33 production140 and 
may contribute to elevated Il33 expression in Scnn1b-Tg mice.15,16 One may speculate that 
IL-13 synthesis in the airway epithelium from naïve Scnn1b-Tg is induced by elevated levels 
of IL-33. This assumption is supported by the observation of an IL-13 production in airway 
epithelial cells from WT mice after administration of rIL-33 (Figure 10). 
In addition to IL-33, ionomycin stimulated Il13 expression by murine primary tracheal 
epithelial cell cultures from WT and Scnn1b-Tg mice (Figure 8). Ionomycin is an ionophore 
that raises the intracellular Ca2+ concentration and is used to study the intracellular 
production of cytokines in immune cells.75,103,118 In vitro experiments by Kouzaki et al. 
revealed an ionomycin-mediated translocation and release of nuclear-stored IL-33 from 
normal human bronchial airway epithelial cells due to increased Ca2+ concentrations.140 This 
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might suggest that ionomycin promotes IL-33 release, which subsequently induces Il13. 
However the mechanism of ionomycin-mediated Il13 expression in murine primary tracheal 
epithelial cells remains unknown.  
 
 
Figure 22. IL-33-mediated signaling pathway leading to IL-13 expression in airway epithelial 
cells. Red highlighted symbols indicate proteins that were studied in the presented study. Dotted 
lines indicate proteins that have been shown to be involved in the signaling pathway according to the 
literature. IL-33 signals through suppression of tumorigenicity 2 (ST2) and IL-1 receptor accessory 
protein (IL-1RAcP) receptor dimers. Upon binding myeloid differentiation primary-response protein 88 
(Myd88), the kinases IL1R-associated kinase 1 (IRAK1) and IRAK4, and the adapter protein TNF 
receptor-associated factor 6 (TRAF6) are recruited. This leads to activation of the mitogen-activated 
protein kinases (MAPK), including extracellular signal-regulated kinases (ERK), Jun N-terminal 
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4.3 Airway surface dehydration and IL-13-induced mucin 
hypersecretion act synergistically in the in vivo pathogenesis 
of airway mucus plugging 
In muco-obstructive airway diseases such as CF, COPD, and asthma, abnormal mucus 
production and/or hydration leads to highly viscous and adhesive mucus associated with 
impaired MCC. Although the initial reasons for airway mucus obstruction differ between 
muco-obstructive lung diseases, airway mucus plugging is often driven by both pathologies 
the overproduction of mucins and airway dehydration. In CF lung disease, mucus 
obstruction is primarily caused by airway dehydration and associated with mucin 
hypersecretion.141 In COPD and asthma, inflammation in response to different triggers 
including tobacco smoke and inhaled allergens, respectively, initially induces mucin 
hypersecretion leading to airway obstruction.142 Several studies also indicated that mucus 
hyperconcentration is a critical point in chronic bronchitis, which is a common clinical feature 
of asthma and COPD.31,32,143 Further, cigarette smoke was shown to induce ASL volume 
depletion by the loss of the CFTR function144,145, ascribing airway dehydration also to the 
pathogenesis of COPD. IL-13 plays a pivotal role in the overproduction of mucins, thereby 
contributing to airway mucus plugging. Besides asthma, COPD and CF are also associated 
with type 2 inflammation including increased IL-13 levels that might contribute to mucin 
hypersecretion.62,64,65 Lately, efforts have been undertaken to understand the biophysical 
mechanism of mucus plugging27, but the relative contribution of airway surface dehydration 
and IL-13-mediated mucin hypersecretion to the in vivo pathogenesis of airway mucus 
obstruction is not known. Therefore, the phenotype of Scnn1b-Tg mice lacking IL-13 
(Scnn1b-Tg/Il13-/-) was studied and Scnn1b-Tg mice (Scnn1b-Tg/Il13+/-) were compared to 
IL-13-over-expressing mice (Il13-Tg/Il13+/-). It will be referred to Scnn1b-Tg and Il13-Tg mice 
to discuss the comparison of Scnn1b-Tg/Il13+/- and Il13-Tg/Il13+/- mice. To gain new insights 
in the combined effects of both defects, Scnn1b-Tg/Il13-Tg/Il13-/- mice were generated.  
Previous studies demonstrated that GCM and spontaneous as well as allergen-induced type 
2 airway inflammation in neonatal/juvenile Scnn1b-Tg mice can be abrogated by the 
deletion of IL-4Rα146 or Stat695. The direct impact of IL-13 in Scnn1b-Tg mice with 
spontaneous type 2 airway inflammation, including increased IL-13 and IL-4 levels, is 
unclear with both cytokines signaling through IL-4Rα/Stat6.147 In juvenile Scnn1b-Tg mice 
lacking IL-13, decreased mucin expression levels accompanied by absence of goblet cells 
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were observed (Figure 12 and Figure 13). This is consistent with previous findings 
demonstrating that IL-13 is sufficient to mediate goblet cell differentiation.61,148 However, 
Scnn1b-Tg/Il13-/- mice still developed severe airway mucus obstruction and airway 
inflammation including neutrophilia and eosinophilia (Figure 12 and Figure 16). Consistent 
with a recent report by Gehrig et al., these data demonstrate that mucus plugging occurs 
independent of mucin hypersecretion in Scnn1b-Tg mice.94 The number of eosinophils was 
only slightly reduced in Scnn1b-Tg/Il13-/- mice compared to Scnn1b-Tg/Il13+/- mice 
suggesting that IL-4, IL-5 and eotaxin149, known to be up-regulated in juvenile Scnn1b-Tg 
mice15,95, may compensate for recruitment of eosinophils during spontaneous type 2 airway 
inflammation in juvenile Scnn1b-Tg mice.  
Consistent with previous reports76,77, strong GCM and a highly increased mucin expression 
were observed in Il13-Tg mice and this was less pronounced in Scnn1b-Tg mice. 
Nonetheless, juvenile Scnn1b-Tg mice were characterized by severe airway mucus 
plugging, whereas under conditions of IL-13-mediated mucin hypersecretion (Il13-Tg mice) 
airway mucus obstruction was less severe (Figure 12). This observation was not only 
manifested in the quantity of mucus content but also in the number of mice showing mucus 
plugging. Less Il13-Tg mice were affected by mucus obstruction than Scnn1b-Tg mice. 
According to Button et al. mucus dehydration and mucin hypersecretion can cause mucus 
hyperconcentration leading to impaired clearance.27 Mucus clearance efficiency was 
impaired in juvenile Scnn1b-Tg mice and resulted in severe mucus plugging. In contrast, in 
Il13-Tg mice mucociliary transport was not affected enabling a better clearance of the 
released mucus (Figure 15). A critical factor that mediates effective MCC is airway 
hydration. In vitro studies revealed that IL-13 down-regulates Na+ transport and increases 
the activity of Cl- channels.89,90 This IL-13-mediated hypersecretory effect was further 
supported in vivo in IL-13 treated mice.88 Proper MCC in Il13-Tg mice might be ascribed to a 
hypersecretory phenotype that prevents severe airway mucus plugging in the presence of 
mucus overproduction by hydrating the airway surface. In patients with asthma, MCC was 
found to be impaired, but to a lesser extent compared to other chronic airway diseases.43 
Future studies are needed to evaluate the impact of the IL-13-mediated hypersecretory 
effect on MCC in patients with asthma. Although Il13-Tg mice displayed no impairment of 
MCC, excessive mucin production still leads to mucus accumulation in Il13-Tg mice 
suggesting that effective MCC does not necessarily prevent airway mucus obstruction. 
Recent studies demonstrated an involvement of IL-13 in tethering the mucus layer to airway 
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epithelial cells.53 Thus, mucus adhesion to the airway surface might be another factor 
contributing to mucus plugging in Il13-Tg mice.  
In contrast to juvenile mice, mucus plugging in main axial airways was similar in  
Scnn1b-Tg/Il13-/- and Il13-Tg/Il13-/- mice at neonatal age (Figure 12 and Figure 18). This 
could be explained by age-dependent differences in the localization of mucus plugs. 
Longitudinal studies by Mall et al. demonstrated that mucus plugging in Scnn1b-Tg mice 
originates in the trachea in the first week of life and then extends into proximal and distal 
airways in juvenile mice.15 However, µ-CT-based analysis of all airways revealed a 
significantly increased mucus score for neonatal Scnn1b-Tg/Il13-/- mice compared to  
Il13-Tg/Il13-/- mice (Figure 19) demonstrating that mucus plugging is more severe in 
neonatal Scnn1b-Tg/Il13-/- compared to Il13-Tg/Il13-/- mice. These data might indicate that 
mucus plugging in the trachea and/or distal airways contribute to an overall severe muco-
obstructive phenotype in neonatal Scnn1b-Tg/Il13-/- mice. 
Inflammatory cells not only affect mucus accumulation through the induction of mucin 
production (e.g. via cytokines), they also alter mucus viscosity. Neutrophil-generated 
oxidation crosslinks mucin polymers to stiffen mucus in CF airways.35 A recent study by 
Dunican et al. proposes that eosinophil-driven oxidation contributes to increased mucus 
viscosity in asthma.19 Juvenile Scnn1b-Tg and Il13-Tg mice were characterized by 
eosinophilic and neutrophilc infiltration (Figure 16), as reported recently.15,77,95,99 Besides the 
prominent effect of IL-13 on eosinophil recruitment, IL-13 has also been implicated with 
neutrophil accumulation.150 These data indicate that eosinophilic and neutrophilc infiltration 
contributes to airway inflammation in both mouse models and thus might affect mucus 
rheology. 
Based on the data obtained so far, it was hypothesized that both defects might reinforce 
each other when mediating mucus obstruction. This assumption is supported by 
observations gained from Scnn1b-Tg/Il13-Tg/Il13-/- mice exhibiting both airway surface 
dehydration and IL-13-mediated mucin hypersecretion. Scnn1b-Tg/Il13-Tg/Il13-/- mice died 
within the first week of life (Figure 17). Histological evaluation of the main stem bronchi 
revealed excessive airway mucus obstruction partially plugging the whole airway lumen 
(Figure 18). µ-CT measurements of the whole lung confirmed this observation on a global 
scale and displayed severe mucus plugging (Figure 19). Moreover, Scnn1b-Tg/Il13-Tg/Il13-/- 
mice were characterized by severe atelectasis, a common feature of CF151,152 and asthma1, 
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resulting from the occlusion of airways with mucus. Neonatal Scnn1b-Tg/Il13-/- and  
Il13-Tg/Il13-/- mice also displayed mucus plugging and atelectaic regions, but to a lesser 
extent and with a milder effect on mortality (Figure 17 and Figure 19). It was concluded that 
severe airway mucus plugging causes neonatal death in Scnn1b-Tg/Il13-Tg/Il13-/- mice. 
Thus, these data support the hypothesis that airway surface dehydration and IL-13-induced 
mucin hypersecretion contribute synergistically to the pathogenesis of airway mucus 
obstruction.  
Another factor that substantiates the hypothesis comes from the treatment study. Hypertonic 
saline is used therapeutically to improve airway surface hydration and MCC in chronic 
airway diseases.153 In Scnn1b-Tg mice, preventive treatment with 7 % HS had beneficial 
effects on mucus obstruction.124 However, treatment with 7 % HS in newborn  
Scnn1b-Tg/Il13-Tg/Il13-/- mice did not rescue mice suggesting that airway hydration alone is 
not sufficient to ameliorate severe airway mucus plugging in dehydrated airways with IL-13-
induced mucin overproduction (Figure 21). Further studies are needed to find an effective 
treatment strategy. Besides the improvement of airway hydration, it might be beneficial to 
consider biophysical mucus properties. This could be achieved by using mucolytic agents, 
which disrupt the mucus gel structure causing a reduced mucus viscosity and thereby 
improving mucus clearance. N-acetylcysteine, which is used in patients with COPD, might 
be a potential mucolytic drug.154 To affect both pathogenic defects, a treatment combining 
airway hydration and mucolytic agents might prevent severe mucus plugging in  
Scnn1b-Tg/Il13-Tg/Il13-/- mice.  
4.4 Muc5ac and Muc5b contribute to airway mucus plugging 
The identification of distinct features of the major respiratory mucins Muc5ac and Muc5b 
indicates that the mucus composition is critical for mucus plugging. Muc5b was found to be 
essential for effective MCC and airway defense57, whereas Muc5ac impedes mucus 
detachment from airway surfaces53, and contributes to AHR and mucus plugging during 
allergic inflammation54. Most studies only investigated the effects of IL-13 on Muc5ac 
production demonstrating that IL-13 regulates Muc5ac via the induction of the transcription 
factors Spdef155 and Foxa386. This is also reflected by the data gained from Il13-Tg mice 
(Figure 13 and Figure 14). In contrast, the regulation of Muc5b by IL-13 is poorly 
understood.42 By looking into Muc5b expression, the obtained data suggest that IL-13 
(in)directly affects Muc5b expression. Muc5b transcripts were up-regulated in Il13-Tg mice, 
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and tended to be reduced in Scnn1b-Tg mice lacking IL-13 (Figure 13). Chen et al. identified 
MUC5B as an FOXA3-regulated gene86, and Guo et al. recently showed a binding site of 
SPDEF in upstream regions of MUC5AC and MUC5B in A549 cells.156 In Il13-Tg mice, 
Muc5b transcription might be mediated by Spdef and/or Foxa3. In Scnn1b-Tg mice, 
increased Muc5ac and Muc5b levels were not associated with an up-regulation of Spdef and 
Foxa3. One may speculate that mucin expression occurs independent of Spdef/Foxa3 in 
Scnn1b-Tg mice. This assumption is supported by a recent observation indicating Muc5ac 
and Muc5b production in neonatal Spdef-deficient Scnn1b-Tg mice.157 Mucin expression in 
Scnn1b-Tg mice might be regulated by an IL-13-mediated MAPK65 or PI3K-NFAT158 
pathway, or other mucin stimulating factors, such as IL-1β and TNF-α159, known to be  
up-regulated in juvenile Scnn1b-Tg mice.15,16 Further studies are needed to clarify the 
transcriptional mucin regulation in response to IL-13 and in Scnn1b-Tg mice.  
Emerging evidence suggests that Muc5ac plays a crucial role for mucus adhesion. First, in 
fatal asthma specimen Shimura et al. observed that released mucus is tethered to goblet 
cells160, and goblet cells in human airways are supposed to produce primarily MUC5AC.28,30 
Second, mucus analysis in piglets indicated that MUC5AC connects goblet cells with 
MUC5B-containing mucus.161 Third, Bonser et al. recently demonstrated that MUC5AC-rich 
mucus is tethered to airway epithelial cells, thereby making the mucus more adhesive.53 In 
neonatal and juvenile Scnn1b-Tg/Il13-/- mice exhibiting severe mucus plugging, mucin 
expression was dominated by Muc5b as shown by baseline Muc5ac expression, elevated 
Muc5b levels, and a low Muc5ac/Muc5b ratio (Figure 13 and Figure 20). These data 
suggest that Muc5ac might be less required for mucus plugging on dehydrated airway 
surfaces. In Scnn1b-Tg mice, mucus adhesion might be rather caused by periciliary 
compression due to dehydration-mediated hyperconcentrated mucus.92 Mucin expression in 
neonatal Il13-/- mice was low, but was characterized by a high Muc5ac/Muc5b ratio. This 
observation might reflect recent finding of an increased expression of type 2 signature 
genes including Muc5ac at the neonatal/juvenile age.95,162 Mucus plugs in juvenile Il13-Tg 
mice are more heterogeneous, because Muc5ac and Muc5b levels were highly upregulated 
(Figure 13). When compared to Scnn1b-Tg mice, the mucus in Il13-Tg mice can be 
described as Muc5ac-rich. Increased Muc5ac content may promote mucus adherence53 in 
Il13-Tg mice that might cause mucus plug formation despite effective mucociliary transport. 
However, these data let assume that both Muc5ac and Muc5b contribute to mucus plugging.  
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In neonatal Il13-Tg/Il13-/- and Scnn1b-Tg/Il13-Tg/Il13-/- mice, total mucin expression levels 
were elevated to similar levels (Figure 20) suggesting that it is not the mucin quantity per se 
that determines the severity of mucus obstruction. In neonatal Scnn1b-Tg/Il13-Tg/Il13-/- 
mice, airway dehydration might exaggerate mucus plugging. Further, neonatal Il13-Tg/Il13-/- 
and Scnn1b-Tg/Il13-Tg/Il13-/- mice revealed similar high Muc5ac and Muc5b expression 
levels and a similar high Muc5ac/Muc5b ratio, again reflecting an IL-13-dependent high 
Muc5ac content compared to Scnn1b-Tg/Il13-/- mice. Since Il13-Tg/Il13-/- mice did not die 
due to lethal airway mucus plugging, Muc5ac-rich mucus might not be the determining 
factor, which further supports the hypothesis that both mucins have an adverse effect on 
mucus obstruction. In line with this, Ehre et al. reported that overexpression of Muc5ac in 
mice does not impair MCC and is insufficient to trigger mucus plugging.163 The authors also 
demonstrated that Muc5ac-containing mucus forms a thicker mucus layer than Muc5b-rich 
mucus.163 A Muc5ac-mediated thick mucus layer might further favor mucus obstruction in 
neonatal Scnn1b-Tg/Il13-Tg/Il13-/- mice with age-related small airway diameters. One may 
speculate that this might play a role in patients, since small airways are affected by mucus 
plugging in CF, COPD, and asthma.9,16,22,164,165  
4.5 Conclusions and future perspectives 
This study demonstrates that under conditions of muco-obstructive lung disease associated 
with type 2 airway inflammation, the airway epithelium provides sources of IL-13. For the 
first time, this study shows that epithelial IL-13 production is directly induced by IL-33 and 
this is mediated by the St2/Myd88/p38 signaling pathway. Considering that IL-33 serves as 
an alarmin in epithelial cells, these data indicate that the airway epithelium itself triggers 
epithelial IL-13 production in an autocrine/paracrine manner. This supports the concept that 
the airway epithelium is not only an important effector tissue but also an important mediator 
of pulmonary inflammation that contributes to the orchestration of type 2 inflammation. 
Further, it was demonstrated that airway epithelium-specific (over)expression of IL-13 is 
sufficient to cause muco-obstructive lung disease characterized by mucus plugging 
associated with overproduction of mucins, severe GCM, and airway inflammation. If the 
human airway epithelium is able to produce IL-13, this will be interesting to study in tissue 
samples from patients with chronic airway diseases, such as COPD and asthma. The use of 
primary airway epithelial cell cultures from patients and healthy controls might confirm a 
relevance of the IL-33/ST2-driven pathway for the epithelial IL-13 production in the human 
system.  
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This study provides novel insights into the relative roles and combined effects of airway 
surface dehydration and IL-13-induced mucin hypersecretion on the in vivo pathogenesis of 
airway mucus obstruction. GCM and increased mucin expression were abrogated in the 
absence of IL-13, but severe mucus plugging persisted in muco-static airways of  
Scnn1b-Tg/Il13-/- mice suggesting that the constitutive mucin secretion is sufficient to cause 
airway mucus obstruction on dehydrated airway surfaces. Further, IL-13-induced mucin 
hypersecretion (Il13-Tg) caused less severe mucus plugging than airway surface 
dehydration (Snnn1b-Tg), and the presence of both defects leads to fatal mucus plugging 
(Scnn1b-Tg/Il13-Tg/Il13-/-). Differences in the severity of mucus plugging might be ascribed 
to the mucus clearance efficiency that was reduced in Scnn1b-Tg mice but was not impaired 
in Il13-Tg mice. To better understand the mechanism of mucus plugging under conditions of 
IL-13-induced mucin hypersecretion, it would be of great interest to study how the gel-on-
brush model considering mucus hyperconcentration and periciliary compression is 
applicable in the Il13-Tg mouse model and of course in patients with asthma. This might be 
achieved by confocal microscopy and by determining the mucus osmotic pressure. This 
study further suggests that airway surface dehydration and IL-13-induced mucin 
hypersecretion act synergistically and have a detrimental effect on the pathogenesis of 
airway mucus obstruction. This is supported by the observation that preventive airway 
hydration treatment alone did not reduce lethal airway mucus plugging in  
Scnn1b-Tg/Il13-Tg/Il13-/- mice. A combination of agents improving airway hydration and 
mucolytic drugs, which decrease mucus viscosity by disrupting its structure, might be more 
beneficial. This study further suggests that both Muc5ac and Muc5b contribute to mucus 
plugging, but also point toward an impact of Muc5ac-rich mucus. IL-13 overexpressing mice 
revealed considerable higher levels of Muc5ac that could facilitate mucus adhesion. 
Knowledge about the distribution of Muc5ac and Muc5b within mucus plugs in the studied 
mouse models (e.g. by immunohistochemistry) might also give new insights into the 
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